{
  "status": "success",
  "message": "Library retrieved successfully",
  "metadata": {
    "id": "b0b8ed2c-bcb1-4fd8-bb37-471becf9d253",
    "owner_id": null,
    "title": "first library",
    "created_at": "2025-11-26T13:40:23.890514Z",
    "updated_at": "2025-11-26T13:40:23.890514Z",
    "stats": {
      "total_papers": 14,
      "total_extracts": 286,
      "total_links": 33
    }
  },
  "data": {
    "papers": [
      {
        "id": "0921e75c-47a4-41c8-9633-6c0c0f1fc95d",
        "title": "LITHIUM IN THE TREATMENT OF BIPOLAR DISORDER: PHARMACOLOGY AND PHARMACOGENETICS",
        "filename": "nihms6298.pdf",
        "storage_path": "0921e75c-47a4-41c8-9633-6c0c0f1fc95d/original.pdf",
        "abstract": "After decades of research, the mechanism of action of lithium in preventing recurrences of bipolar disorder remains only partially understood. Lithium research is complicated by absence of suitable animal models of bipolar disorder and by having to rely on in vitro studies of peripheral tissues. A number of distinct hypotheses emerged over the years, but none has been conclusively supported or rejected. The common theme emerging from pharmacological and genetic studies is that lithium affects multiple steps in cellular signalling, usually enhancing basal and inhibiting stimulated activities. Some of the key nodes of these regulatory networks include GSK3, CREB, and Na + -K + ATPase. Genetic and pharmacogenetic studies are starting to generate promising findings, but remain limited by small sample sizes. As full responders to lithium seem to represent a unique clinical population, there is inherent value and need for studies of lithium responders. Such studies will be an opportunity to uncover specific effects of lithium in those individuals who clearly benefit from the treatment.",
        "added_at": "2025-11-26T13:40:24.030702Z"
      },
      {
        "id": "10e6f40a-e864-4a66-9695-d93693e7a398",
        "title": "VU Research Portal Association of polygenic score for major depression with response to lithium in patients with bipolar disorder Amare, Azmeraw T; Baune, Bernhard T; Major Depressive Disorder Working Group of the",
        "filename": "Association_of_polygenic_score_for_major_depression_with_response_to_lithium_in_patients_with_bipolar_disorder.pdf",
        "storage_path": "10e6f40a-e864-4a66-9695-d93693e7a398/original.pdf",
        "abstract": "document version Publisher's PDF, also known as Version of record document license Article 25fa Dutch Copyright Act Link to publication in VU Research Portal citation for published version (APA)",
        "added_at": "2025-11-26T13:40:24.030702Z"
      },
      {
        "id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
        "title": "Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania",
        "filename": "Double_blind_randomized_placebo_controll.pdf",
        "storage_path": "174bc307-7fde-44a3-81f0-c4af3de84fe4/original.pdf",
        "abstract": "Background: Considerable amount of biochemical data supports the potential involvement of protein kinase C in the pathophysiology and treatment of bipolar disorder. The aim of this double-blind, placebo-controlled study was to investigate the efficacy and tolerability of tamoxifen as an adjunct to lithium for the treatment of acute mania in hospitalized bipolar patients. Methods: Eligible participants were 40 inpatients, between the ages of 19 and 49 years with current manic episode. Patients were randomly allocated to lithium (1-1.2 mEq/L) + tamoxifen 80 mg/day (group A) or lithium (1-1.2 mEq/L) + placebo (group B) for a 6-week, double-blind, placebo-controlled study. The principal measure of outcome was the Young Mania Rating Scale. The raters used standardized instructions for Young Mania Rating Scale. Results: Young Mania Rating Scale scores improved with tamoxifen. The difference between the two protocols was significant as indicated by the effect of the group, the between-subjects factor (F = 5.41, df =1, p = 0.02). A significant difference was observed on the Positive and Negative Syndrome Scale total score at week 6 in the two groups. The difference between the two groups in the frequency of side effects was not significant except for fatigue that occurred more often in the tamoxifen group. Limitations: Tamoxifen is an antagonist of estrogen receptor as well. Conclusion: The results demonstrate that the combination of tamoxifen with lithium was superior to lithium alone for the rapid reduction of manic symptoms. The combined use of tamoxifen with lithium was well tolerated in these acutely manic patients.",
        "added_at": "2025-11-26T13:41:29.289641Z"
      },
      {
        "id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
        "title": "Effect of Clozapine, Haloperidol, or M100907 on Phencyclidine-Activated Glutamate Efflux in the Prefrontal Cortex",
        "filename": "adams2001.pdf",
        "storage_path": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24/original.pdf",
        "abstract": "Background: The increase in glutamate efflux in the prefrontal cortex by the psychotomimetic drugs phencyclidine (PCP) and ketamine may produce the dopaminergic and some of the behavioral effects of these drugs. Here, we examined whether antipsychotic drugs influence this increase. Methods: The effect of haloperidol, clozapine or the 5-HT 2A antagonist, M100907, on PCP-induced increase in cortical glutamate efflux was examined by microdialysis. Because previous studies had suggested that M100907 attenuates some behavioral effects of PCP, we also examined the effect of M100907 on PCP-induced cortical and accumbal dopamine activation while making concomitant measures of locomotion and stereotypy. Results: Haloperidol, clozapine or M100907 did not significantly block hyperglutamatergic effects of PCP. M100907 was ineffective in inhibiting the dopaminergic and motoric effects of PCP. Conclusions: These results contrast previous findings with glutamatergic drugs, such as AMPA antagonists or group II metabotropic glutamate agonists, that blocked glutamatergic and motoric effects of PCP. Thus, the PCP glutamate activation model lacks predictive validity for conventional antipsychotics; however, this model may be useful for design of novel classes of drugs that target those symptoms of schizophrenia that are not generally treated with monoamine-based antipsychotics.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a",
        "title": "bdi.12998",
        "filename": "bdi.12998.pdf",
        "storage_path": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a/original.pdf",
        "abstract": "adherence and some comorbidities, both evidence and personal experience indicate that lithium should nowadays be still the drug of choice for the treatment of BD in the majority of patients.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
        "title": "Integrative analysis of lithium treatment associated effects on brain structure and peripheral gene expression reveals novel molecular insights into mechanism of action",
        "filename": "s41398-020-0784-z.pdf",
        "storage_path": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126/original.pdf",
        "abstract": "Lithium is a highly effective medication for bipolar disorder, but its mechanism of action remains unknown. In this study, brain MRI scans and blood samples for gene expression (total of 110 scans and 109 blood samples) were collected from 21 bipolar subjects before and after 2 and 8 weeks of lithium monotherapy and at the same timepoints from untreated 16 healthy controls. We used linear mixed-effects models to identify brain structural features and genes with expression changed after lithium treatment, with correction for multiple testing, and correlated their concurrent changes to identify molecular pathways associated with lithium effects. There are significant increases in gray matter fraction, global cortical thickness, and the frontal and parietal cortices after 8 weeks of lithium treatment (corrected p < 0.05). Volume increases were also seen for putamen, hippocampus, thalamic nuclei, and thalamic substructures. Several genes showed significant expression changes, and 14 gene pathways were identified for the present integration analysis. Of these, nine pathways had significant correlations with structural changes (FDR < 0.05). Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlated with structural changes in multiple regions. Mediation analysis showed that the sphingomyelin metabolism pathway is associated with HAM-D change (p < 0.01), and this effect is mediated via the volume of mediodorsal thalamus (p < 0.03). In summary, the integration of lithium effects on brain structural and peripheral gene expression changes revealed effects on several neurotrophic molecular pathways, which provides further insights into the mechanism of lithium action.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
        "title": "Exploring Lithium's Transcriptional Mechanisms of Action in Bipolar Disorder: A Multi-Step Study",
        "filename": "s41386-019-0556-8_reference.pdf",
        "storage_path": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274/original.pdf",
        "abstract": "Lithium has been the first-line treatment for bipolar disorder (BD) for more than six decades. Although the molecular effects of lithium have been studied extensively and gene expression changes are generally believed to be involved, the specific mechanisms of action that mediate mood regulation are still not known. In this study, a multi-step approach was used to explore the transcriptional changes that may underlie lithium's therapeutic efficacy. First, we identified genes that are associated both with lithium exposure and with BD, and second, we performed differential expression analysis of these genes in brain tissue samples from BD patients (n=42) and healthy controls (n=42). To identify genes that are regulated by lithium exposure, we used high-sensitivity RNA-sequencing of corpus callosum (CC) tissue samples from lithium-treated (n=8) and non-treated (n=9) rats. We found that lithium exposure significantly affected 1108 genes (FDR <0.05), 702 up-regulated and 406 down-regulated. These genes were mostly enriched for molecular functions related to signal transduction, including well-established lithium-related pathways such as mTOR and Wnt signaling. To identify genes with differential expression in BD, we performed expression quantitative trait loci (eQTL) analysis on BD-associated genetic variants from the most recent genome-wide association study (GWAS) using three different gene expression databases. We found 307 unique eQTL genes regulated by BD-associated variants, of which 12 were also significantly modulated by lithium treatment in rats. Two of these showed differential expression in the CC of BD cases: RPS23 was significantly down-regulated (p=0.0036, fc=0.80), while GRIN2A showed suggestive evidence of down-regulation in BD (p=0.056, fc=0.65). Crucially, GRIN2A was also significantly up-regulated by lithium in the rat brains (p=2.2e-5, fc=1.6), which suggests that modulation of GRIN2A expression may be a part of the therapeutic effect of the drug. These results indicate that the recent upsurge in research on this central component of the glutamatergic system, as a target of novel therapeutic agents for affective disorders, is warranted and should be intensified.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
        "title": "A specific amyloid-b protein assembly in the brain impairs memory",
        "filename": "lesne 2006.pdf",
        "storage_path": "a1ccbd68-78dd-46e0-841b-08427704a08a/original.pdf",
        "abstract": null,
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "ae6e03da-5843-4bb8-b6a9-e08180f34956",
        "title": "Neurotrophin signaling: many exciting surprises!",
        "filename": "18_2006_Article_6010.pdf",
        "storage_path": "ae6e03da-5843-4bb8-b6a9-e08180f34956/original.pdf",
        "abstract": "Neurotrophins are growth factors implicated in the development and maintenance of different neuronal populations in the nervous system. Neurotrophins bind to two sets of receptors, Trk receptor tyrosine kinases and the p75 NTR receptor, to activate several different signaling pathways that mediate various biological functions. While Trk receptor activation has been well-studied and triggers the well-characterized Ras/Rap-MAPK, PI3K-Akt, and PLCÎ³-PKC cascades, p75 NTR signaling is more complex, and its in vivo significance has not yet been completely determined. In the last few years, p75 NTR has received much attention mainly due to recent findings describing pro-neurotrophins as new ligands for the receptor and the ability of the receptor to form different complexes with other transmembrane proteins. This review will update the neurotrophin signaling pathways known for Trk receptors to include newly identified Trk-interacting molecules and will address surprising new findings that suggest a role for p75 NTR in different receptor complexes and functions.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "caf42807-00f1-42f1-b07b-d3ab715b7863",
        "title": "Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression",
        "filename": "fnins-12-00386.pdf",
        "storage_path": "caf42807-00f1-42f1-b07b-d3ab715b7863/original.pdf",
        "abstract": "Human and animal studies suggest an intriguing link between mitochondrial diseases and depression. Although depression has historically been linked to alterations in monoaminergic pharmacology and adult hippocampal neurogenesis, new data increasingly implicate broader forms of dampened plasticity, including plasticity within the cell. Mitochondria are the cellular powerhouse of eukaryotic cells, and they also regulate brain function through oxidative stress and apoptosis. In this paper, we make the case that mitochondrial dysfunction could play an important role in the pathophysiology of depression. Alterations in mitochondrial functions such as oxidative phosphorylation (OXPHOS) and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms. However, the data in relation to antidepressant drug effects are contradictory: some studies reveal they have no effect on mitochondrial function or even potentiate dysfunction, whereas other studies show more beneficial effects. Overall, the data suggest an intriguing link between mitochondrial function and depression that warrants further investigation. Mitochondria could be targeted in the development of novel antidepressant drugs, and specific forms of mitochondrial dysfunction could be identified as biomarkers to personalize treatment and aid in early diagnosis by differentiating between disorders with overlapping symptoms.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
        "title": "Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats",
        "filename": "Protein_kinase_C_regulates_mood_related.pdf",
        "storage_path": "cff3064b-6a8c-4e61-ba97-0ee25e061e78/original.pdf",
        "abstract": "The neurobiological mechanisms underlying the pathophysiology and therapeutics of bipolar disorder are still unknown. In recent years, protein kinase C (PKC) has emerged as a potential key player in mania. To further investigate the role of this signaling system in mood regulation, we examined the effects of PKC modulators in behavioral tests modeling several facets of bipolar disorder and in adult hippocampal cell proliferation in rats. Our results showed that a single injection of the PKC inhibitors tamoxifen (80 mg/kg, i.p.) and chelerythrine (3 mg/kg, s.c.) attenuated amphetamine-induced hyperlocomotion and decreased risk-taking behavior, supporting the efficacy of PKC blockade in acute mania. Moreover, chronic exposure to tamoxifen (10 mg/kg/day, i.p., for 14 days) or chelerythrine (0.3 mg/kg/day, s.c., for 14 days) caused depressive-like behavior in the forced swim test, and resulted in a reduction of cell proliferation in the dentate gyrus of the hippocampus. Finally, we showed that, contrary to the PKC inhibitors, the PKC activator phorbol 12-myristate 13-acetate (PMA) enhanced risk-taking behavior and induced an antidepressant-like effect. Taken together, these findings support the involvement of PKC in regulating opposite facets of bipolar disorder, and emphasize a major role for PKC in this disease.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "d26c70af-64c5-47c4-bf88-8ce3bd8f93a9",
        "title": "Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders",
        "filename": "zpg238.pdf",
        "storage_path": "d26c70af-64c5-47c4-bf88-8ce3bd8f93a9/original.pdf",
        "abstract": "Brain derived neurotrophic factor (BDNF) is the most prevalent growth factor in the central nervous system (CNS). It is essential for the development of the CNS and for neuronal plasticity. Because BDNF plays a crucial role in development and plasticity of the brain, it is widely implicated in psychiatric diseases. This review provides a summary of clinical and preclinical evidence for the involvement of this ubiquitous growth factor in major depressive disorder, schizophre-nia, addiction, Rett syndrome, as well as other psychiatric and neurodevelopmental diseases. In addition, the review includes a discussion of the role of BDNF in the mechanism of action of pharmacological therapies currently used to treat these diseases, such antidepressants and antipsychotics. The review also covers a critique of experimental therapies such as BDNF mimetics and discusses the value of BDNF as a target for future drug development.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
        "title": "Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies",
        "filename": "2018 Artigas et al Eur Neuropsychopharmacology part II .pdf",
        "storage_path": "e96d6a98-f38b-4429-b1ba-4c31de579587/original.pdf",
        "abstract": "In the second part we focus on two treatment strategies that may overcome the main limitations of current antidepressant drugs. First, we review the experimental and clinical evidence supporting the use of glutamatergic drugs as fast-acting antidepressants. Secondly, we review the involvement of microRNAs in the pathophysiology of major depressive disorder (MDD) and the use of small RNAs (e.g.., small interfering RNAs or siRNAs) to knockdown serotonergic genes and induce antidepressant-like responses in experimental animals. The development of glutamatergic agents is a promising venue for antidepressant drug development, given the antidepressant properties of the non-competitive NMDA receptor antagonist ketamine. Its unique properties appear to result from the activation of AMPA receptors by a metabolite [(2S,6S;2R,6R)-hydroxynorketamine (HNK)] and mTOR signaling. These effects increase synaptogenesis in prefrontal cortical pyramidal neurons and enhance serotonergic neurotransmission via descending inputs to the raphe nuclei. This view is supported by the cancellation of ketamine's antidepressant-like effects by inhibition of serotonin synthesis. We also review existing evidence supporting the involvement of microRNA (miRNA) in MDD and the preclinical use of RNA interference (RNAi) strategies to target genes involved in antidepressant response. Many miRNAs have been associated to MDD, some of which -e.g., miR-135-target genes involved in antidepressant actions. Likewise, we review the use of SSRI-conjugated siRNA (small interfering RNA) to evoke faster and/or more effective antidepressant-like responses. Intranasal application of sertraline-conjugated siRNAs directed to 5-HT1A receptors and SERT evoked much faster changes of pre-and postsynaptic antidepressant markers than those produced by fluoxetine.",
        "added_at": "2025-11-26T13:44:07.891083Z"
      },
      {
        "id": "ea7930cf-93c7-4975-a8b2-15e8698e6991",
        "title": "New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview",
        "filename": "lithium review.pdf",
        "storage_path": "ea7930cf-93c7-4975-a8b2-15e8698e6991/original.pdf",
        "abstract": null,
        "added_at": "2025-11-26T13:44:07.891083Z"
      }
    ],
    "extracts": {
      "claims": [
        {
          "id": "84d6eec7-ac14-4f03-aff5-95b68ad5a314",
          "paper_id": "0921e75c-47a4-41c8-9633-6c0c0f1fc95d",
          "job_id": "cce76725-e180-4742-9d95-b4e214fc5c5f",
          "type": "claim",
          "content": {
            "reasoning": "This claim identifies a unique clinical subpopulation and asserts the scientific value of studying them specifically.",
            "rephrased_claim": "Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s7"
              },
              {
                "source_element_id": "abs-d1-p1-s8"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:22.213525Z"
        },
        {
          "id": "ec67c767-39fb-4ccb-be89-27fd2a97ae56",
          "paper_id": "0921e75c-47a4-41c8-9633-6c0c0f1fc95d",
          "job_id": "cce76725-e180-4742-9d95-b4e214fc5c5f",
          "type": "claim",
          "content": {
            "reasoning": "This is a core claim synthesizing the paper's findings about lithium's mechanism of action across pharmacological and genetic studies.",
            "rephrased_claim": "Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:22.213525Z"
        },
        {
          "id": "daf03de6-256f-437d-ba0a-a16ee56bfc87",
          "paper_id": "0921e75c-47a4-41c8-9633-6c0c0f1fc95d",
          "job_id": "cce76725-e180-4742-9d95-b4e214fc5c5f",
          "type": "claim",
          "content": {
            "reasoning": "This is a core interpretive claim about how lithium produces its therapeutic effects, representing the paper's conclusion about the mechanism.",
            "rephrased_claim": "Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",
            "source_elements": [
              {
                "source_element_id": "d35-p1-s3"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:22.213525Z"
        },
        {
          "id": "2d5e05cd-d871-42cb-b864-4c444cd9994c",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "claim",
          "content": {
            "reasoning": "This is the primary novel finding of the study, establishing a molecular genetic link between major depression risk variants and lithium treatment outcomes in bipolar disorder patients.",
            "rephrased_claim": "Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.",
            "source_elements": [
              {
                "source_element_id": "d13-p1-s1"
              },
              {
                "source_element_id": "d13-p1-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:28:35.451356Z"
        },
        {
          "id": "97c81d6e-e353-4dd4-9a45-2c12671217e8",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "claim",
          "content": {
            "reasoning": "This quantifies the core finding of the paper, demonstrating the magnitude of the genetic effect on treatment response.",
            "rephrased_claim": "Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.",
            "source_elements": [
              {
                "source_element_id": "d13-p1-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:28:35.451356Z"
        },
        {
          "id": "b1827ba4-9d49-468c-bb64-2c90e09f1a3a",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "claim",
          "content": {
            "reasoning": "This represents an original finding linking major depression genetic risk to clinical phenotype severity in bipolar disorder.",
            "rephrased_claim": "Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.",
            "source_elements": [
              {
                "source_element_id": "d13-p1-s3"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:28:35.451356Z"
        },
        {
          "id": "4429ac65-e370-4a8f-8b4f-25845d777d97",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "claim",
          "content": {
            "reasoning": "This claim references previously described clinical observations and existing notions about Kraepelinian manic depression, which the current study's findings support but did not originally establish.",
            "rephrased_claim": "Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.",
            "source_elements": [
              {
                "source_element_id": "d13-p2-s1"
              },
              {
                "source_element_id": "d13-p2-s2"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:28:35.451356Z"
        },
        {
          "id": "4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "claim",
          "content": {
            "reasoning": "This is a generalizable interpretation of the paper's findings combined with prior schizophrenia polygenic score results, representing a broader insight about genetic comorbidity and treatment response.",
            "rephrased_claim": "The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.",
            "source_elements": [
              {
                "source_element_id": "d13-p3-s1"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:28:35.451356Z"
        },
        {
          "id": "97bdd2dc-de39-4a2f-a3b2-d374fbd202e0",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "claim",
          "content": {
            "reasoning": "This is a novel hypothesis generated by the study's findings, proposing distinct mechanisms of lithium action in depression versus bipolar disorder based on the genetic evidence.",
            "rephrased_claim": "Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.",
            "source_elements": [
              {
                "source_element_id": "d13-p4-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:28:35.451356Z"
        },
        {
          "id": "76a66954-b970-4954-87d8-b1658e951b14",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "claim",
          "content": {
            "reasoning": "This is a background statement referencing existing biochemical data, not an original contribution of this paper.",
            "rephrased_claim": "Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s1"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:26:25.177396Z"
        },
        {
          "id": "2b69a477-3fa3-4a96-9a36-77b58dda0554",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "claim",
          "content": {
            "reasoning": "This is the core finding and original contribution of the paper, demonstrated through their double-blind, placebo-controlled trial.",
            "rephrased_claim": "Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s7"
              },
              {
                "source_element_id": "abs-d1-p1-s8"
              },
              {
                "source_element_id": "abs-d2-p1-s1"
              },
              {
                "source_element_id": "d13-p1-s1"
              },
              {
                "source_element_id": "d13-p1-s17"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:26:25.177396Z"
        },
        {
          "id": "e94c05b3-ab35-4b9f-86a5-009428370c62",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "claim",
          "content": {
            "reasoning": "This is an original safety and tolerability conclusion from the study's findings.",
            "rephrased_claim": "The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s10"
              },
              {
                "source_element_id": "abs-d2-p1-s2"
              },
              {
                "source_element_id": "d13-p1-s3"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:26:25.177396Z"
        },
        {
          "id": "fd1d30e8-f335-4a58-a073-46c46d8eab1f",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "claim",
          "content": {
            "reasoning": "This is an original finding about the speed of therapeutic response observed in their study.",
            "rephrased_claim": "Tamoxifen induces a rapid antimanic effect as early as day 7 of treatment.",
            "source_elements": [
              {
                "source_element_id": "d13-p1-s15"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:26:25.177396Z"
        },
        {
          "id": "068c21c4-d223-4419-a3a6-e74d3c4d6bf0",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "claim",
          "content": {
            "reasoning": "This is a mechanistic interpretation and theoretical claim made by the authors based on their findings linking PKC inhibition to rapid antimanic effects.",
            "rephrased_claim": "Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.",
            "source_elements": [
              {
                "source_element_id": "d13-p1-s15"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:26:25.177396Z"
        },
        {
          "id": "bc25b976-8b05-4146-9fb5-13f238c08ee9",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This proposes a specific application for the PCP/ketamine model in drug development, focusing on non-monoaminergic therapeutic approaches for treatment-resistant symptoms.",
            "rephrased_claim": "The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s8"
              },
              {
                "source_element_id": "d10-p6-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:52.588045Z"
        },
        {
          "id": "3610ee8a-4b5d-40c5-a800-21bdec74117f",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This establishes the foundational mechanism that the paper investigates, though it references previous work establishing this relationship.",
            "rephrased_claim": "The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s1"
              },
              {
                "source_element_id": "d10-p1-s2"
              },
              {
                "source_element_id": "d10-p5-s1"
              },
              {
                "source_element_id": "d10-p5-s2"
              },
              {
                "source_element_id": "d10-p5-s3"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T13:09:52.588045Z"
        },
        {
          "id": "591b4592-fa77-435a-ac20-f3cbb5263f56",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This is the principal empirical finding of the study demonstrating that conventional antipsychotic drugs do not affect PCP-induced glutamate activation.",
            "rephrased_claim": "Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              },
              {
                "source_element_id": "d10-p1-s1"
              },
              {
                "source_element_id": "d10-p6-s1"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:52.588045Z"
        },
        {
          "id": "49b4d9c8-db47-4ae4-9471-c57e91439ecc",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This is a direct experimental finding showing that 5-HT2A antagonism does not affect PCP-induced dopamine release or motor behavior.",
            "rephrased_claim": "M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              },
              {
                "source_element_id": "d10-p6-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:52.588045Z"
        },
        {
          "id": "f08ed696-e6ae-4062-9a3e-2a086d625f62",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This is an interpretive claim about the underlying mechanism, concluding that glutamate activation occurs upstream of or independently from monoaminergic systems.",
            "rephrased_claim": "PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.",
            "source_elements": [
              {
                "source_element_id": "d10-p1-s1"
              },
              {
                "source_element_id": "d10-p6-s3"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:52.588045Z"
        },
        {
          "id": "a6a0b022-06db-4138-bd34-61d976fd59a6",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This is a core conclusion about the utility of the PCP model for predicting antipsychotic efficacy, suggesting limitations for drug screening based on this mechanism.",
            "rephrased_claim": "The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s8"
              },
              {
                "source_element_id": "d10-p1-s5"
              },
              {
                "source_element_id": "d10-p6-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:52.588045Z"
        },
        {
          "id": "66319bf8-0459-4763-8cea-9412aba98c25",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This establishes the foundational mechanism that the paper investigates, though it references previous work establishing this relationship.",
            "rephrased_claim": "The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s1"
              },
              {
                "source_element_id": "d10-p1-s2"
              },
              {
                "source_element_id": "d10-p5-s1"
              },
              {
                "source_element_id": "d10-p5-s2"
              },
              {
                "source_element_id": "d10-p5-s3"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:31:46.068270Z"
        },
        {
          "id": "fdcdf1bb-91e2-474a-817a-8c79abdf372e",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This is the principal empirical finding of the study demonstrating that conventional antipsychotic drugs do not affect PCP-induced glutamate activation.",
            "rephrased_claim": "Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              },
              {
                "source_element_id": "d10-p1-s1"
              },
              {
                "source_element_id": "d10-p6-s1"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:31:46.068270Z"
        },
        {
          "id": "7248d5f5-3c2b-4aae-9daf-66dfecd35127",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This is a direct experimental finding showing that 5-HT2A antagonism does not affect PCP-induced dopamine release or motor behavior.",
            "rephrased_claim": "M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              },
              {
                "source_element_id": "d10-p6-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:31:46.068270Z"
        },
        {
          "id": "c1cc9e43-ed77-466f-98ee-a4ba62cb7888",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This is an interpretive claim about the underlying mechanism, concluding that glutamate activation occurs upstream of or independently from monoaminergic systems.",
            "rephrased_claim": "PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.",
            "source_elements": [
              {
                "source_element_id": "d10-p1-s1"
              },
              {
                "source_element_id": "d10-p6-s3"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:31:46.068270Z"
        },
        {
          "id": "fc094750-8733-464d-b345-437a216b0769",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This is a core conclusion about the utility of the PCP model for predicting antipsychotic efficacy, suggesting limitations for drug screening based on this mechanism.",
            "rephrased_claim": "The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s8"
              },
              {
                "source_element_id": "d10-p1-s5"
              },
              {
                "source_element_id": "d10-p6-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:31:46.068270Z"
        },
        {
          "id": "25286171-950a-4c3c-abf6-dbab297a47a8",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "claim",
          "content": {
            "reasoning": "This proposes a specific application for the PCP/ketamine model in drug development, focusing on non-monoaminergic therapeutic approaches for treatment-resistant symptoms.",
            "rephrased_claim": "The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s8"
              },
              {
                "source_element_id": "d10-p6-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:31:46.068270Z"
        },
        {
          "id": "0878e73e-5f4f-4dcb-812c-48b086d33682",
          "paper_id": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a",
          "job_id": "21b3ee0a-4713-4efd-84b0-63402ecee689",
          "type": "claim",
          "content": {
            "reasoning": "This is the central argument of the paper, stating that lithium should be the preferred treatment choice for bipolar disorder over other available options.",
            "rephrased_claim": "Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s1"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:25:12.745312Z"
        },
        {
          "id": "bd479224-5c5a-404d-9c45-468f2e68bcef",
          "paper_id": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a",
          "job_id": "21b3ee0a-4713-4efd-84b0-63402ecee689",
          "type": "claim",
          "content": {
            "reasoning": "This claim references findings from the BALANCE study, indicating it is a restated claim from another source supporting the paper's argument.",
            "rephrased_claim": "Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.",
            "source_elements": [
              {
                "source_element_id": "d1-p3-s1"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:25:12.745312Z"
        },
        {
          "id": "10899945-abc8-4bbb-b952-ac3c573494ab",
          "paper_id": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a",
          "job_id": "21b3ee0a-4713-4efd-84b0-63402ecee689",
          "type": "claim",
          "content": {
            "reasoning": "This claim is based on a Danish registry study comparing lamotrigine to lithium, restating findings from another source.",
            "rephrased_claim": "Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.",
            "source_elements": [
              {
                "source_element_id": "d1-p3-s3"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:25:12.745312Z"
        },
        {
          "id": "75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e",
          "paper_id": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a",
          "job_id": "21b3ee0a-4713-4efd-84b0-63402ecee689",
          "type": "claim",
          "content": {
            "reasoning": "This claim references the MAP study findings about lithium's superiority over carbamazepine, indicating it is restated from another source.",
            "rephrased_claim": "Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.",
            "source_elements": [
              {
                "source_element_id": "d1-p3-s4"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:25:12.745312Z"
        },
        {
          "id": "d4e77fc9-7d46-473c-86f9-13b018308d00",
          "paper_id": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a",
          "job_id": "21b3ee0a-4713-4efd-84b0-63402ecee689",
          "type": "claim",
          "content": {
            "reasoning": "This claim synthesizes findings from meta-analyses about lithium's comparative effectiveness, restating conclusions from other research.",
            "rephrased_claim": "Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.",
            "source_elements": [
              {
                "source_element_id": "d1-p4-s1"
              },
              {
                "source_element_id": "d1-p4-s2"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:25:12.745312Z"
        },
        {
          "id": "fee98cc5-6e1b-4570-ac74-0c3966fa8c32",
          "paper_id": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a",
          "job_id": "21b3ee0a-4713-4efd-84b0-63402ecee689",
          "type": "claim",
          "content": {
            "reasoning": "This claim restates meta-analytical findings comparing lithium to mood-stabilizing anticonvulsants.",
            "rephrased_claim": "Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.",
            "source_elements": [
              {
                "source_element_id": "d1-p4-s3"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:25:12.745312Z"
        },
        {
          "id": "d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64",
          "paper_id": "334f6c50-b4c9-45cf-8941-5d51f1d3ed0a",
          "job_id": "21b3ee0a-4713-4efd-84b0-63402ecee689",
          "type": "claim",
          "content": {
            "reasoning": "This is an original synthesis and conclusion by the authors about lithium's unique comprehensive efficacy profile across all phases of bipolar disorder.",
            "rephrased_claim": "Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.",
            "source_elements": [
              {
                "source_element_id": "d1-p5-s1"
              },
              {
                "source_element_id": "d1-p5-s2"
              },
              {
                "source_element_id": "d1-p5-s3"
              },
              {
                "source_element_id": "d1-p5-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:25:12.745312Z"
        },
        {
          "id": "33a04b51-6903-488b-91e5-7fd6dbb7c78f",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "claim",
          "content": {
            "reasoning": "This describes the main structural brain findings that the paper demonstrates through their longitudinal MRI study of lithium treatment effects.",
            "rephrased_claim": "Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:25:35.368058Z"
        },
        {
          "id": "c6b2f073-3921-470e-a771-ed36fdce8709",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "claim",
          "content": {
            "reasoning": "This represents a core mechanistic finding linking gene expression pathways to structural changes, revealing insights into how lithium works.",
            "rephrased_claim": "Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s8"
              },
              {
                "source_element_id": "d16-p2-s11"
              },
              {
                "source_element_id": "d16-p2-s12"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:25:35.368058Z"
        },
        {
          "id": "12694b8a-03de-462a-a0da-b8412687c380",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "claim",
          "content": {
            "reasoning": "This is a key mechanistic claim establishing a pathway from molecular changes through structural changes to clinical improvement.",
            "rephrased_claim": "The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s9"
              },
              {
                "source_element_id": "d16-p5-s1"
              },
              {
                "source_element_id": "d16-p5-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:25:35.368058Z"
        },
        {
          "id": "4ca80348-cbf0-476a-9ece-9ec40dc89dc2",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "claim",
          "content": {
            "reasoning": "This is the overarching conclusion about lithium's mechanism of action based on the integrative analysis approach used in the study.",
            "rephrased_claim": "Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s10"
              },
              {
                "source_element_id": "d16-p1-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:25:35.368058Z"
        },
        {
          "id": "9ed653c6-b9bf-45f1-aa0c-0e81fe511c50",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "claim",
          "content": {
            "reasoning": "This claim establishes the connection between the two types of measurements and suggests neurotrophic mechanisms underlie lithium's effects.",
            "rephrased_claim": "Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.",
            "source_elements": [
              {
                "source_element_id": "d16-p2-s10"
              },
              {
                "source_element_id": "d16-p2-s11"
              },
              {
                "source_element_id": "d16-p3-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:25:35.368058Z"
        },
        {
          "id": "8c60294a-ff96-4ed1-8774-69b5ec363317",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "claim",
          "content": {
            "reasoning": "This is a core claim about the therapeutic relevance of targeting the glutamatergic system, specifically GRIN2A, which the paper presents as a novel insight derived from their multi-step investigation.",
            "rephrased_claim": "GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s15"
              },
              {
                "source_element_id": "d19-p7-s6"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:41.861458Z"
        },
        {
          "id": "1a142c2f-a016-4716-8019-a883e04a6b5f",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "claim",
          "content": {
            "reasoning": "This is the paper's primary mechanistic claim linking lithium's molecular effects to its therapeutic action through a specific gene, representing an original contribution about how lithium works.",
            "rephrased_claim": "Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s14"
              },
              {
                "source_element_id": "d19-p7-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:41.861458Z"
        },
        {
          "id": "27a93479-31ed-49b7-950e-3cf4b7671182",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "claim",
          "content": {
            "reasoning": "This claim represents the paper's interpretation of their findings regarding the breadth versus specificity of lithium's effects, challenging a more targeted mechanism hypothesis.",
            "rephrased_claim": "The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.",
            "source_elements": [
              {
                "source_element_id": "d19-p4-s3"
              },
              {
                "source_element_id": "d19-p4-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:41.861458Z"
        },
        {
          "id": "5930f19c-a19e-4fee-ab43-352f872aa7ad",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "claim",
          "content": {
            "reasoning": "This is an original finding from the study about lithium's effects on the immune system, contributing to understanding of its molecular mechanisms of action.",
            "rephrased_claim": "Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.",
            "source_elements": [
              {
                "source_element_id": "d19-p3-s5"
              },
              {
                "source_element_id": "d19-p3-s6"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:41.861458Z"
        },
        {
          "id": "acf52d27-7c31-4096-af22-9f53124e5954",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "claim",
          "content": {
            "reasoning": "This is the core claim of the paper as stated in the abstract and demonstrated throughout: that AÎ²*56 is responsible for memory deficits in a way that is independent of neurodegeneration.",
            "rephrased_claim": "A specific 56-kDa soluble amyloid-beta assembly, termed AÎ²*56, causes memory impairment independently of amyloid plaques or neuronal loss.",
            "source_elements": [
              {
                "source_element_id": "d1-p1-s5"
              },
              {
                "source_element_id": "d1-p1-s6"
              },
              {
                "source_element_id": "d1-p1-s7"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T11:16:18.121339Z"
        },
        {
          "id": "339a5afb-fcce-4a86-8db0-61c5b7820889",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "claim",
          "content": {
            "reasoning": "This is a key experimental finding that establishes causality rather than just correlation between AÎ²*56 and memory impairment.",
            "rephrased_claim": "Purified AÎ²*56 from impaired transgenic mouse brains disrupts memory when administered to young rats, demonstrating a direct causal relationship between this protein assembly and cognitive impairment.",
            "source_elements": [
              {
                "source_element_id": "d1-p1-s6"
              },
              {
                "source_element_id": "d1-p1-s7"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T11:16:18.121339Z"
        },
        {
          "id": "981409ae-f92e-4784-9066-87b4decde650",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "claim",
          "content": {
            "reasoning": "This is the paper's proposed clinical significance and interpretation of their findings for understanding human Alzheimer's disease progression.",
            "rephrased_claim": "AÎ²*56 may contribute to cognitive deficits in early-stage Alzheimer's disease before the development of plaques or significant neuronal loss.",
            "source_elements": [
              {
                "source_element_id": "d1-p1-s7"
              },
              {
                "source_element_id": "d1-p5-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T11:16:18.121339Z"
        },
        {
          "id": "b859f853-c1b7-4bae-afcc-1d8552492731",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "claim",
          "content": {
            "reasoning": "This is an original structural insight about how amyloid-beta oligomerizes, which is a novel contribution about the nature of these protein assemblies.",
            "rephrased_claim": "Soluble amyloid-beta assemblies form a stable ladder of oligomers comprised of trimers and multiples of trimers, with trimers being the fundamental assembly unit in vivo.",
            "source_elements": [
              {
                "source_element_id": "d1-p6-s11"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T11:16:18.121339Z"
        },
        {
          "id": "9f159ba9-7ed1-4c2b-9d87-f770d8888d11",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "claim",
          "content": {
            "reasoning": "This represents an important mechanistic claim about how AÎ²*56 causes memory deficits, distinguishing it from mechanisms involving permanent structural damage.",
            "rephrased_claim": "AÎ²*56 impairs memory by inducing transient physiological alterations rather than permanent neuropathological changes in the brain.",
            "source_elements": [
              {
                "source_element_id": "d1-p19-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T11:16:18.121339Z"
        },
        {
          "id": "32039099-7adb-448e-9ab9-b51dbee4866b",
          "paper_id": "ae6e03da-5843-4bb8-b6a9-e08180f34956",
          "job_id": "17169b3f-1c9d-4ec6-a500-302019030843",
          "type": "claim",
          "content": {
            "reasoning": "This is a core claim about the dual receptor binding mechanism of neurotrophins, which is central to understanding their signaling complexity.",
            "rephrased_claim": "Neurotrophins activate multiple signaling pathways by binding to two distinct receptor types: Trk receptor tyrosine kinases and the p75 NTR receptor.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:24:52.951731Z"
        },
        {
          "id": "e39212d2-772a-428b-a2fa-5e5f17b75391",
          "paper_id": "ae6e03da-5843-4bb8-b6a9-e08180f34956",
          "job_id": "17169b3f-1c9d-4ec6-a500-302019030843",
          "type": "claim",
          "content": {
            "reasoning": "This claim contrasts the well-understood Trk signaling with the more complex and incompletely understood p75 NTR signaling, establishing a key knowledge gap.",
            "rephrased_claim": "While Trk receptor signaling pathways are well-characterized, p75 NTR signaling is more complex and its in vivo significance remains incompletely determined.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s3"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:24:52.951731Z"
        },
        {
          "id": "4f2c7d9b-21a1-4c57-bf10-bdc5fe88cf6f",
          "paper_id": "ae6e03da-5843-4bb8-b6a9-e08180f34956",
          "job_id": "17169b3f-1c9d-4ec6-a500-302019030843",
          "type": "claim",
          "content": {
            "reasoning": "This claim highlights recent discoveries about p75 NTR function, specifically its ability to bind pro-neurotrophins and form receptor complexes.",
            "rephrased_claim": "p75 NTR can bind pro-neurotrophins as ligands and form different complexes with other transmembrane proteins, expanding understanding of its signaling capabilities.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:24:52.951731Z"
        },
        {
          "id": "e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4",
          "paper_id": "ae6e03da-5843-4bb8-b6a9-e08180f34956",
          "job_id": "17169b3f-1c9d-4ec6-a500-302019030843",
          "type": "claim",
          "content": {
            "reasoning": "This is stated in the conclusion as a summary claim about the ongoing mystery and potential of neurotrophin research.",
            "rephrased_claim": "Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.",
            "source_elements": [
              {
                "source_element_id": "d20-p1-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:24:52.951731Z"
        },
        {
          "id": "ee17cb0b-702d-46ca-bfed-fc7e1a1da63a",
          "paper_id": "caf42807-00f1-42f1-b07b-d3ab715b7863",
          "job_id": "22232244-ae24-4e34-b74d-6cf9270c6585",
          "type": "claim",
          "content": {
            "reasoning": "This is a core claim of the paper stated directly in the abstract, presenting the main argument that mitochondrial dysfunction plays a key role in depression pathophysiology.",
            "rephrased_claim": "Mitochondrial dysfunction plays an important role in the pathophysiology of depression.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:06.390261Z"
        },
        {
          "id": "703e323f-781d-49a1-9b29-a076270691a6",
          "paper_id": "caf42807-00f1-42f1-b07b-d3ab715b7863",
          "job_id": "22232244-ae24-4e34-b74d-6cf9270c6585",
          "type": "claim",
          "content": {
            "reasoning": "This is a core mechanistic claim about how mitochondrial changes lead to depressive symptoms, representing an original contribution about the temporal relationship.",
            "rephrased_claim": "Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:06.390261Z"
        },
        {
          "id": "ffdad4fb-9055-44ab-99f8-e87b94a53af3",
          "paper_id": "caf42807-00f1-42f1-b07b-d3ab715b7863",
          "job_id": "22232244-ae24-4e34-b74d-6cf9270c6585",
          "type": "claim",
          "content": {
            "reasoning": "This is stated as a conclusion in the paper and represents the authors' interpretation of the evidence regarding stress-induced mitochondrial changes in depression.",
            "rephrased_claim": "Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.",
            "source_elements": [
              {
                "source_element_id": "d11-p1-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:06.390261Z"
        },
        {
          "id": "e2a99bc5-1b56-47bf-8fe6-dc5063fe7060",
          "paper_id": "caf42807-00f1-42f1-b07b-d3ab715b7863",
          "job_id": "22232244-ae24-4e34-b74d-6cf9270c6585",
          "type": "claim",
          "content": {
            "reasoning": "This represents a core mechanistic claim about the cascade of events linking mitochondrial dysfunction to depression, synthesizing the proposed pathological pathway.",
            "rephrased_claim": "Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.",
            "source_elements": [
              {
                "source_element_id": "d11-p1-s5"
              },
              {
                "source_element_id": "d11-p1-s6"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:06.390261Z"
        },
        {
          "id": "07787c05-d861-4709-ab6b-53fbbf35ae62",
          "paper_id": "caf42807-00f1-42f1-b07b-d3ab715b7863",
          "job_id": "22232244-ae24-4e34-b74d-6cf9270c6585",
          "type": "claim",
          "content": {
            "reasoning": "This is a forward-looking claim based on the paper's synthesis suggesting mitochondria as therapeutic targets, representing an original contribution to treatment strategy.",
            "rephrased_claim": "Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.",
            "source_elements": [
              {
                "source_element_id": "d11-p1-s7"
              },
              {
                "source_element_id": "abs-d1-p1-s8"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:29:06.390261Z"
        },
        {
          "id": "38c47f6f-9f2f-4c59-95e5-89c32b7e6241",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "This is emphasized in the abstract and discussion as a major conclusion about PKC's bidirectional role in mood regulation.",
            "rephrased_claim": "PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.",
            "source_elements": [
              {
                "source_element_id": "d22-p4-s4"
              },
              {
                "source_element_id": "abs-d1-p1-s7"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:47.321416Z"
        },
        {
          "id": "679feb8f-e96a-4b0e-a6bc-f3447c3b774b",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "This is stated as a main finding in the abstract and discussion, establishing PKC as a key player in mood regulation and bipolar disorder.",
            "rephrased_claim": "Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s2"
              },
              {
                "source_element_id": "d22-p1-s1"
              },
              {
                "source_element_id": "d22-p1-s2"
              },
              {
                "source_element_id": "abs-d1-p1-s7"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:47.321416Z"
        },
        {
          "id": "ae3c78a3-aaea-4b95-88c9-0997465c58c7",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "The paper's primary contribution shows that PKC inhibitors attenuate manic-like behaviors, supporting their potential as antimanic agents.",
            "rephrased_claim": "PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "d22-p1-s2"
              },
              {
                "source_element_id": "d22-p5-s1"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:47.321416Z"
        },
        {
          "id": "9ccfdc45-aa16-4546-abcf-7333a5b07623",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "This is a core finding showing that sustained PKC inhibition leads to depression-like phenotypes, an important insight for understanding PKC's role in mood regulation.",
            "rephrased_claim": "Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              },
              {
                "source_element_id": "d22-p7-s3"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:47.321416Z"
        },
        {
          "id": "bfdfd15f-1d66-4cb0-bef9-66b87c492ad1",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "The paper demonstrates that PKC activators produce effects opposite to inhibitors, establishing bidirectional regulation of mood by PKC.",
            "rephrased_claim": "PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              },
              {
                "source_element_id": "d22-p1-s2"
              },
              {
                "source_element_id": "d22-p6-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:47.321416Z"
        },
        {
          "id": "f46b86ed-7e0f-49ea-a715-326d1b9e3bf5",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "The paper presents this as novel evidence linking PKC to neurogenesis, representing a new contribution to understanding PKC's role in brain plasticity.",
            "rephrased_claim": "PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.",
            "source_elements": [
              {
                "source_element_id": "d22-p8-s9"
              },
              {
                "source_element_id": "d22-p8-s12"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T13:09:47.321416Z"
        },
        {
          "id": "44d9d6c3-956a-4cda-9524-e2ff9c9eeb31",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "This is stated as a main finding in the abstract and discussion, establishing PKC as a key player in mood regulation and bipolar disorder.",
            "rephrased_claim": "Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s2"
              },
              {
                "source_element_id": "d22-p1-s1"
              },
              {
                "source_element_id": "d22-p1-s2"
              },
              {
                "source_element_id": "abs-d1-p1-s7"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:32:50.580357Z"
        },
        {
          "id": "c989f22f-aa0e-401c-81e7-044a608fa580",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "The paper's primary contribution shows that PKC inhibitors attenuate manic-like behaviors, supporting their potential as antimanic agents.",
            "rephrased_claim": "PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "d22-p1-s2"
              },
              {
                "source_element_id": "d22-p5-s1"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:32:50.580357Z"
        },
        {
          "id": "982b4346-2957-418d-8cf9-da662ceb1b52",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "This is a core finding showing that sustained PKC inhibition leads to depression-like phenotypes, an important insight for understanding PKC's role in mood regulation.",
            "rephrased_claim": "Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              },
              {
                "source_element_id": "d22-p7-s3"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:32:50.580357Z"
        },
        {
          "id": "8558ce87-1df5-4a7f-88b6-63efb39b40e9",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "The paper demonstrates that PKC activators produce effects opposite to inhibitors, establishing bidirectional regulation of mood by PKC.",
            "rephrased_claim": "PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              },
              {
                "source_element_id": "d22-p1-s2"
              },
              {
                "source_element_id": "d22-p6-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:32:50.580357Z"
        },
        {
          "id": "250087d7-a16f-41a4-a719-305cb8574ec4",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "The paper presents this as novel evidence linking PKC to neurogenesis, representing a new contribution to understanding PKC's role in brain plasticity.",
            "rephrased_claim": "PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.",
            "source_elements": [
              {
                "source_element_id": "d22-p8-s9"
              },
              {
                "source_element_id": "d22-p8-s12"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:32:50.580357Z"
        },
        {
          "id": "1b1b68ed-d73c-418f-abed-03484f767103",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "claim",
          "content": {
            "reasoning": "This is emphasized in the abstract and discussion as a major conclusion about PKC's bidirectional role in mood regulation.",
            "rephrased_claim": "PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.",
            "source_elements": [
              {
                "source_element_id": "d22-p4-s4"
              },
              {
                "source_element_id": "abs-d1-p1-s7"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:32:50.580357Z"
        },
        {
          "id": "5d2a635d-4bc1-47e6-8418-e59d0ea7c895",
          "paper_id": "d26c70af-64c5-47c4-bf88-8ce3bd8f93a9",
          "job_id": "c1e7f963-9e09-4e28-994c-7fe01bf78882",
          "type": "claim",
          "content": {
            "reasoning": "This is a restatement of established knowledge about BDNF's role in the CNS, not an original contribution of this review paper.",
            "rephrased_claim": "Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s1"
              },
              {
                "source_element_id": "abs-d1-p1-s2"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:22:33.331895Z"
        },
        {
          "id": "f1026128-41d0-42c3-903f-91b85f829d75",
          "paper_id": "d26c70af-64c5-47c4-bf88-8ce3bd8f93a9",
          "job_id": "c1e7f963-9e09-4e28-994c-7fe01bf78882",
          "type": "claim",
          "content": {
            "reasoning": "This claim synthesizes the review's evidence but represents an established understanding in the field rather than a novel insight from this paper.",
            "rephrased_claim": "BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s3"
              },
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "d29-p1-s3"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:22:33.331895Z"
        },
        {
          "id": "e637a57c-7d6e-4115-9772-d33043296384",
          "paper_id": "d26c70af-64c5-47c4-bf88-8ce3bd8f93a9",
          "job_id": "c1e7f963-9e09-4e28-994c-7fe01bf78882",
          "type": "claim",
          "content": {
            "reasoning": "This describes established knowledge about BDNF's role in pharmacological treatment mechanisms, not an original finding of this review.",
            "rephrased_claim": "BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:22:33.331895Z"
        },
        {
          "id": "1e7f51f6-eaca-4408-ae8b-756c1531362e",
          "paper_id": "d26c70af-64c5-47c4-bf88-8ce3bd8f93a9",
          "job_id": "c1e7f963-9e09-4e28-994c-7fe01bf78882",
          "type": "claim",
          "content": {
            "reasoning": "This is a statement about the importance of BDNF based on its established biological functions, serving as justification for research rather than a novel claim.",
            "rephrased_claim": "BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.",
            "source_elements": [
              {
                "source_element_id": "d29-p1-s1"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:22:33.331895Z"
        },
        {
          "id": "7f20b8cb-7031-4eda-94a6-62bf085ad3a4",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This claim summarizes the mechanistic understanding of how ketamine works as an antidepressant, which is a core scientific insight reviewed in the paper about glutamatergic antidepressant strategies.",
            "rephrased_claim": "Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p2-s1"
              },
              {
                "source_element_id": "abs-d1-p2-s2"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "574de708-d2c9-4a84-a3ab-666c829c2ca0",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This describes the neurobiological mechanism through which ketamine produces its antidepressant effects, representing a key scientific understanding about how glutamatergic drugs work.",
            "rephrased_claim": "Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p2-s3"
              },
              {
                "source_element_id": "abs-d1-p2-s4"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "d3692f18-f6e0-43f6-8900-8c465cb99821",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This claim establishes a specific relationship between a microRNA and depression-related mechanisms, which is a core insight about the role of miRNAs in depression.",
            "rephrased_claim": "MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p3-s2"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "54c4e069-99aa-4b45-9a6b-a1c75b1af627",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This is an original contribution of the paper demonstrating a novel RNA interference strategy that achieves more rapid antidepressant effects than conventional treatments.",
            "rephrased_claim": "Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p3-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "e4e083c6-321d-43d1-a9e2-8cde729e53f8",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This claim describes a specific neurobiological finding about the role of dynorphin in depression, establishing a relationship between this neuropeptide system and depressive behaviors.",
            "rephrased_claim": "Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.",
            "source_elements": [
              {
                "source_element_id": "d14-p3-s2"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "c22169ca-25d4-454c-83d7-dc34195e21f6",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This claim proposes a unifying mechanism across different antidepressant interventions, representing a core insight about convergent pathways in antidepressant action.",
            "rephrased_claim": "Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.",
            "source_elements": [
              {
                "source_element_id": "d14-p4-s5"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "1a636000-95d9-4c4f-8a2d-e203b07f0ad5",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This claim establishes a region-specific relationship between BDNF and depression, providing anatomical specificity to the neurotrophic hypothesis of depression.",
            "rephrased_claim": "BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.",
            "source_elements": [
              {
                "source_element_id": "d14-p7-s5"
              }
            ],
            "original_claim_by_paper": false
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "0ff4b45b-d46b-405d-8744-56b371122414",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This is a core interpretive claim of the paper about the significance of ketamine for challenging existing paradigms and opening new directions in antidepressant development.",
            "rephrased_claim": "Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.",
            "source_elements": [
              {
                "source_element_id": "d15-p1-s1"
              },
              {
                "source_element_id": "d15-p1-s2"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "7edf49c1-fbb0-4c33-9108-69565003a47c",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "claim",
          "content": {
            "reasoning": "This is an original contribution describing a novel approach to using RNA interference for antidepressant treatment that overcomes key technical limitations.",
            "rephrased_claim": "SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.",
            "source_elements": [
              {
                "source_element_id": "d15-p2-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T12:23:28.489223Z"
        },
        {
          "id": "0ccc686b-5be5-4aa5-9360-6c97d148920d",
          "paper_id": "ea7930cf-93c7-4975-a8b2-15e8698e6991",
          "job_id": null,
          "type": "claim",
          "content": {
            "reasoning": "This is a core claim summarizing the paper's central thesis about lithium's mechanism of action across multiple cellular pathways.",
            "rephrased_claim": "Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.",
            "source_elements": [
              {
                "source_element_id": "d35-p1-s3"
              },
              {
                "source_element_id": "d35-p1-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T10:20:14.894717Z"
        },
        {
          "id": "bc544bb8-5c5d-4d1e-9c34-b51e2f339464",
          "paper_id": "ea7930cf-93c7-4975-a8b2-15e8698e6991",
          "job_id": null,
          "type": "claim",
          "content": {
            "reasoning": "This is a core mechanistic claim proposing that lithium's diverse effects are fundamentally mediated by two key molecular targets.",
            "rephrased_claim": "Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.",
            "source_elements": [
              {
                "source_element_id": "d35-p1-s5"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T10:20:14.894717Z"
        },
        {
          "id": "49494958-ed3e-4d55-9ca1-fb94f2be3929",
          "paper_id": "ea7930cf-93c7-4975-a8b2-15e8698e6991",
          "job_id": null,
          "type": "claim",
          "content": {
            "reasoning": "This is a core claim establishing a specific molecular mechanism by which lithium acts as a therapeutic agent in neurodegenerative diseases.",
            "rephrased_claim": "The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.",
            "source_elements": [
              {
                "source_element_id": "d35-p2-s1"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T10:20:14.894717Z"
        },
        {
          "id": "88027d82-ef95-4b58-ad6b-ef7f74e5cb4d",
          "paper_id": "ea7930cf-93c7-4975-a8b2-15e8698e6991",
          "job_id": null,
          "type": "claim",
          "content": {
            "reasoning": "This claim proposes a specific mechanistic pathway for lithium's autophagy-enhancing effects that differs from conventional understanding.",
            "rephrased_claim": "Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.",
            "source_elements": [
              {
                "source_element_id": "d35-p2-s4"
              }
            ],
            "original_claim_by_paper": true
          },
          "created_at": "2025-11-26T10:20:14.894717Z"
        }
      ],
      "observations": [
        {
          "id": "40364bd7-c0bb-4ad4-8d0c-dedc1843e641",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d5-p1-s3"
              }
            ],
            "method_reference": "f8411335-d94d-43b2-acbf-22bec328a1ce",
            "observation_type": "categorical outcome classification",
            "observation_summary": "Patients with bipolar disorder were categorized as 'good responders' to lithium treatment if they had a total Alda score of 7 or higher, while those with lower scores were categorized as poor responders.",
            "quantitative_details": "Alda total score threshold: â¥7 for good responders"
          },
          "created_at": "2025-11-26T12:28:52.219962Z"
        },
        {
          "id": "94231031-d575-4abe-a0d3-15513c2887c1",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d12-p1-s1"
              }
            ],
            "method_reference": "f8411335-d94d-43b2-acbf-22bec328a1ce",
            "observation_type": "statistical result",
            "observation_summary": "No significant association was found between polygenic scores for lumbar spine bone mineral density and lithium treatment response in bipolar patients across all p-value thresholds tested.",
            "quantitative_details": "p > 0.05 for all polygenic score association tests at different p value thresholds"
          },
          "created_at": "2025-11-26T12:28:52.219962Z"
        },
        {
          "id": "119c3804-97d4-44ab-b2e9-20ee46ee2bf8",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d12-p1-s1"
              }
            ],
            "method_reference": "f8411335-d94d-43b2-acbf-22bec328a1ce",
            "observation_type": "statistical result",
            "observation_summary": "No significant association was found between polygenic scores for femoral neck mineral density and lithium treatment response in bipolar patients across all p-value thresholds tested.",
            "quantitative_details": "p > 0.05 for all polygenic score association tests at different p value thresholds"
          },
          "created_at": "2025-11-26T12:28:52.219962Z"
        },
        {
          "id": "44f75a62-0e82-4311-b390-682e0d1c10a9",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d12-p1-s1"
              }
            ],
            "method_reference": "f8411335-d94d-43b2-acbf-22bec328a1ce",
            "observation_type": "statistical result",
            "observation_summary": "No significant association was found between polygenic scores for forearm bone mineral density and lithium treatment response in bipolar patients across all p-value thresholds tested.",
            "quantitative_details": "p > 0.05 for all polygenic score association tests at different p value thresholds"
          },
          "created_at": "2025-11-26T12:28:52.219962Z"
        },
        {
          "id": "f8a69e55-3bbb-4773-9451-ac57ae30b9b6",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s7"
              },
              {
                "source_element_id": "abs-d1-p1-s8"
              }
            ],
            "method_reference": "d17a7564-c957-4b98-b1d1-a1e538d03151",
            "observation_type": "statistical result",
            "observation_summary": "Young Mania Rating Scale scores improved with tamoxifen treatment compared to placebo, with a significant group effect (F = 5.41, df = 1, p = 0.02)",
            "quantitative_details": "F = 5.41, df = 1, p = 0.02"
          },
          "created_at": "2025-11-26T12:26:48.817036Z"
        },
        {
          "id": "226aee1c-175e-4e1d-9000-46970679f89a",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s9"
              }
            ],
            "method_reference": "d17a7564-c957-4b98-b1d1-a1e538d03151",
            "observation_type": "statistical result",
            "observation_summary": "A significant difference was observed on the Positive and Negative Syndrome Scale total score at week 6 between tamoxifen and placebo groups",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:48.817036Z"
        },
        {
          "id": "fe6e293f-e32e-4276-952a-9f9da31d6b33",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s10"
              }
            ],
            "method_reference": "d17a7564-c957-4b98-b1d1-a1e538d03151",
            "observation_type": "safety outcome",
            "observation_summary": "The difference between the two groups in the frequency of side effects was not significant except for fatigue, which occurred more often in the tamoxifen group",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:48.817036Z"
        },
        {
          "id": "256602f6-3239-4111-80ee-61003fbf96ff",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s1"
              },
              {
                "source_element_id": "d9-p1-s2"
              },
              {
                "source_element_id": "d9-p1-s3"
              }
            ],
            "method_reference": "d17a7564-c957-4b98-b1d1-a1e538d03151",
            "observation_type": "recruitment outcome",
            "observation_summary": "60 potential study candidates were initially identified, of which 20 patients did not meet study inclusion criteria, resulting in 40 bipolar patients randomized",
            "quantitative_details": "60 potential candidates identified; 20 did not meet inclusion criteria; 40 randomized"
          },
          "created_at": "2025-11-26T12:26:48.817036Z"
        },
        {
          "id": "669fd05d-0bb1-4899-b8e0-bc1de5e81246",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s4"
              }
            ],
            "method_reference": "d17a7564-c957-4b98-b1d1-a1e538d03151",
            "observation_type": "attrition outcome",
            "observation_summary": "One patient from the tamoxifen group and two from the placebo group dropped out of the study, leaving 37 patients who completed the trial",
            "quantitative_details": "1 dropout in tamoxifen group; 2 dropouts in placebo group; 37 completers"
          },
          "created_at": "2025-11-26T12:26:48.817036Z"
        },
        {
          "id": "d33bd70c-83a9-49e2-aa4b-6148ddfac72f",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s5"
              }
            ],
            "method_reference": "d17a7564-c957-4b98-b1d1-a1e538d03151",
            "observation_type": "baseline comparison",
            "observation_summary": "No significant differences were identified between patients randomly assigned to group A (tamoxifen) or group B (placebo) with regard to basic demographic data",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:48.817036Z"
        },
        {
          "id": "aa78cf6b-1c5f-41fd-93c2-42f8b7f1f179",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d6-p1-s4"
              }
            ],
            "method_reference": "d17a7564-c957-4b98-b1d1-a1e538d03151",
            "observation_type": "measurement reliability",
            "observation_summary": "High inter-rater reliability was obtained for SCID (ICC = 0.90), YMRS (ICC = 0.90), PANSS (ICC = 0.89), and HAMD-17 (ICC = 0.85)",
            "quantitative_details": "SCID ICC = 0.90; YMRS ICC = 0.90; PANSS ICC = 0.89; HAMD-17 ICC = 0.85"
          },
          "created_at": "2025-11-26T12:26:48.817036Z"
        },
        {
          "id": "8beab99a-5ea3-4df9-8787-49261c644bd9",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s8"
              },
              {
                "source_element_id": "d9-p5-s9"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "statistical result",
            "observation_summary": "There was no significant difference in dopamine release between vehicle and M100907 pretreated groups in the nucleus accumbens following PCP administration (F=0.81, p=0.62)",
            "quantitative_details": "F=0.81, p=0.62"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "0214f593-c740-4f6d-89ce-eb6bd8d50a00",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p2-s3"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "Extracellular levels of both serotonin and glutamate remained elevated above baseline at the termination of the experiment following PCP administration",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "bbde1fac-b9da-4099-afd9-462489c0a92b",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p3-s2"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "In vehicle pretreated animals, PCP produced a significant increase in prefrontal cortex glutamate (n=9, F=3.3, p<0.001)",
            "quantitative_details": "n=9, F=3.3, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "9dad55ec-cad1-433a-85ac-b6e0d5ac663a",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p3-s3"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "In animals pretreated with clozapine (10 mg/kg, IP) 20 minutes before PCP (5 mg/kg), a significant increase in glutamate was observed (n=7, F=2.04, p<0.05)",
            "quantitative_details": "n=7, F=2.04, p<0.05"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "4b19ea9e-9aac-42c4-8501-7e741b8c595a",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p3-s4"
              },
              {
                "source_element_id": "d9-p3-s5"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "statistical result",
            "observation_summary": "There was no significant difference in glutamate increase between vehicle and clozapine pretreated groups following PCP administration (F=0.96, p=0.48)",
            "quantitative_details": "F=0.96, p=0.48"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "f9265d0f-9202-4076-be7c-b4e10ec57edc",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p4-s1"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "In animals pretreated with haloperidol, PCP produced a significant increase in glutamate (n=9, F=5.51, p<0.001)",
            "quantitative_details": "n=9, F=5.51, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "b18d7f94-f332-4a9c-ae63-8e01978d2d6d",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p4-s2"
              },
              {
                "source_element_id": "d9-p4-s3"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "statistical result",
            "observation_summary": "There was no significant difference in glutamate increase between vehicle and haloperidol pretreated groups following PCP administration (F=0.88, p=0.59)",
            "quantitative_details": "F=0.88, p=0.59"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "909450c5-72be-4057-bcef-2082895ee777",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p4-s4"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "Pretreatment with M100907 (0.1 mg/kg, IP, n=7) produced a similar pattern of increase in extracellular glutamate in the prefrontal cortex as measured in the vehicle group",
            "quantitative_details": "n=7"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "e87e8559-ac0e-46a6-901e-7df01b46b6d5",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p4-s5"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "statistical result",
            "observation_summary": "PCP-induced glutamate activation in the M100907 pretreated group did not reach statistical significance",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "28d498aa-81f6-4717-b9de-2fed2277df7a",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p4-s5"
              },
              {
                "source_element_id": "d9-p4-s6"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "statistical result",
            "observation_summary": "There was no significant difference in glutamate increase between vehicle and M100907 pretreated groups following PCP administration (F=0.28, p=0.99)",
            "quantitative_details": "F=0.28, p=0.99"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "fe4e1078-3bff-46d8-b0a0-6db7e89c0388",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s1"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "experimental outcome",
            "observation_summary": "In vehicle pretreated animals, PCP produced a significant increase in locomotion (n=8, F=3.49, p<0.001)",
            "quantitative_details": "n=8, F=3.49, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "3d8db8ae-434f-42db-8d84-a5e71cef5138",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s1"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "experimental outcome",
            "observation_summary": "In vehicle pretreated animals, PCP produced a significant increase in stereotypy (n=8, F=10, p<0.001)",
            "quantitative_details": "n=8, F=10, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "ff7b5776-ed0e-490e-a4af-f2b3931f5c7e",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s2"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "experimental outcome",
            "observation_summary": "In animals pretreated with M100907, PCP increased locomotion (n=10, F=3.84, p<0.001)",
            "quantitative_details": "n=10, F=3.84, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "123c55ed-7ed9-4757-832b-653b0d1b9fdc",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s3"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "statistical result",
            "observation_summary": "There were no significant differences between vehicle and M100907 pretreated groups in stereotypy following PCP administration",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "6f583c3a-5419-438e-8e9e-0352c93a211b",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s4"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP produced a robust increase in dopamine release in the prefrontal cortex (n=6, F=17.7, p<0.001)",
            "quantitative_details": "n=6, F=17.7, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "27321915-2d7a-43c5-bbea-d71c30ccfc60",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s4"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP produced a smaller but significant increase in dopamine release in the nucleus accumbens (n=8, F=14.1, p<0.001)",
            "quantitative_details": "n=8, F=14.1, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "9c79c86e-600c-4436-ae7f-953b41f88080",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s5"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "experimental outcome",
            "observation_summary": "In M100907 pretreated animals, PCP produced significant dopamine release in the prefrontal cortex (n=7, F=5.8, p<0.001)",
            "quantitative_details": "n=7, F=5.8, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "e79b744a-14a7-4848-894f-9017ab01d395",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s5"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "experimental outcome",
            "observation_summary": "In M100907 pretreated animals, PCP produced significant dopamine release in the nucleus accumbens (n=8, F=6.9, p<0.001)",
            "quantitative_details": "n=8, F=6.9, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "fda0a87d-f7a4-4010-b7cb-82c725c3a9cb",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s6"
              },
              {
                "source_element_id": "d9-p5-s7"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "statistical result",
            "observation_summary": "There was no significant difference in dopamine release between vehicle and M100907 pretreated groups in the prefrontal cortex following PCP administration (F=0.56, p=0.84)",
            "quantitative_details": "F=0.56, p=0.84"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "7f1b9540-6598-40f4-b616-a24d571d414d",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s2"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "experimental outcome",
            "observation_summary": "In animals pretreated with M100907, PCP increased stereotypy (n=10, F=10, p<0.001)",
            "quantitative_details": "n=10, F=10, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "e3fbe170-43b8-4ff8-a570-5f2873b9989b",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s5"
              },
              {
                "source_element_id": "d9-p1-s6"
              },
              {
                "source_element_id": "d9-p1-s7"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "measurement",
            "observation_summary": "Basal extracellular levels of serotonin in the prefrontal cortex were 0.30 Â± 0.02 fmole/L (n=6)",
            "quantitative_details": "0.30 Â± 0.02 fmole/L, n=6"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "8183835c-58b3-4e07-bb79-1e8c3529fcc2",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s3"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "statistical result",
            "observation_summary": "There were no significant differences between vehicle and M100907 pretreated groups in locomotor activity following PCP administration",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "504fb0ab-c56e-4a50-acd4-8c8b7d0b75e2",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s8"
              },
              {
                "source_element_id": "d9-p1-s9"
              },
              {
                "source_element_id": "d9-p1-s10"
              }
            ],
            "method_reference": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
            "observation_type": "measurement",
            "observation_summary": "Basal extracellular levels of dopamine in the nucleus accumbens were 0.96 Â± 0.12 fmole/L (n=16)",
            "quantitative_details": "0.96 Â± 0.12 fmole/L, n=16"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "68b9576c-1c22-4b21-9be6-7f5b0b30829c",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s1"
              },
              {
                "source_element_id": "d9-p1-s2"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "measurement",
            "observation_summary": "Basal extracellular levels of dopamine in the prefrontal cortex were 0.33 Â± 0.03 fmole/L (n=13)",
            "quantitative_details": "0.33 Â± 0.03 fmole/L, n=13"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "d7bbcb06-05be-4a04-a7fc-cbf9d8d31be8",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s3"
              },
              {
                "source_element_id": "d9-p1-s4"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "measurement",
            "observation_summary": "Basal extracellular levels of glutamate in the prefrontal cortex were 0.26 Â± 0.02 pmole/L (n=37)",
            "quantitative_details": "0.26 Â± 0.02 pmole/L, n=37"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "5baeff49-deb4-4c70-abfc-06363cb53603",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p2-s1"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP (5 mg/kg, IP) produced a significant increase in extracellular levels of serotonin in the prefrontal cortex (n=6, F=3.92, p<0.001)",
            "quantitative_details": "n=6, F=3.92, p<0.001"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "674ed3fd-4419-44d9-ad3c-dd0421c3e28e",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p2-s1"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP (5 mg/kg, IP) produced a significant increase in extracellular levels of glutamate in the prefrontal cortex (n=7, F=2.42, p<0.05)",
            "quantitative_details": "n=7, F=2.42, p<0.05"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "e623bac1-71fb-40e4-9eea-369ae5cc5dd2",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p2-s2"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "After PCP administration, serotonin levels quickly increased to a maximal level of 230% above baseline within 20 minutes",
            "quantitative_details": "230% above baseline at 20 minutes post-injection"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "2064e439-550d-48bc-b7fd-28d0da72b766",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p2-s2"
              }
            ],
            "method_reference": "aafa5a4a-2370-4809-964b-420024e61a52",
            "observation_type": "experimental outcome",
            "observation_summary": "After PCP administration, extracellular glutamate levels did not reach a maximal level until 80 minutes post-injection",
            "quantitative_details": "Maximal level at 80 minutes post-injection"
          },
          "created_at": "2025-11-26T13:10:37.475308Z"
        },
        {
          "id": "4a3ea2a6-d40b-4880-89e8-150725c8add3",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s3"
              },
              {
                "source_element_id": "d9-p1-s4"
              },
              {
                "source_element_id": "d9-p1-s5"
              }
            ],
            "method_reference": "e2e61a2e-613e-4b77-8653-eae1a1d90045",
            "observation_type": "measurement",
            "observation_summary": "Basal extracellular glutamate levels in the prefrontal cortex were 0.26 Â± 0.02 pmol/L (n=37)",
            "quantitative_details": "0.26 Â± 0.02 pmol/L, n=37"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "009dfc75-dad8-4d9b-8dc0-c47a1012b83f",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p2-s1"
              },
              {
                "source_element_id": "d9-p2-s2"
              },
              {
                "source_element_id": "d9-p2-s3"
              }
            ],
            "method_reference": "e2e61a2e-613e-4b77-8653-eae1a1d90045",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP (5 mg/kg, IP) produced a significant increase in extracellular glutamate levels in the prefrontal cortex, reaching maximal level at 80 minutes post-injection and remaining elevated through experiment termination",
            "quantitative_details": "n=7, F=2.42, p<0.05; maximal level reached at 80 min post-injection"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "ad02bfd0-9b7d-4dde-ae15-6a735f39ad0b",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p3-s2"
              }
            ],
            "method_reference": "e2e61a2e-613e-4b77-8653-eae1a1d90045",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP (5 mg/kg) produced a significant increase in extracellular glutamate in vehicle-pretreated animals",
            "quantitative_details": "n=9, F=3.3, p<0.001"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "bf838856-55a5-451b-b9bd-85c5016d8abf",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p3-s3"
              },
              {
                "source_element_id": "d9-p3-s4"
              },
              {
                "source_element_id": "d9-p3-s5"
              }
            ],
            "method_reference": "e2e61a2e-613e-4b77-8653-eae1a1d90045",
            "observation_type": "experimental outcome",
            "observation_summary": "Clozapine pretreatment (10 mg/kg, IP) did not significantly block PCP-induced increase in prefrontal cortex glutamate; the increase remained significant in clozapine-pretreated animals",
            "quantitative_details": "Clozapine group: n=7, F=2.04, p<0.05; between-group comparison: F=0.96, p=0.48"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "cb51d3f8-b633-4fa3-8d53-fa776673cc57",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p4-s1"
              },
              {
                "source_element_id": "d9-p4-s2"
              },
              {
                "source_element_id": "d9-p4-s3"
              }
            ],
            "method_reference": "e2e61a2e-613e-4b77-8653-eae1a1d90045",
            "observation_type": "experimental outcome",
            "observation_summary": "Haloperidol pretreatment did not significantly block PCP-induced increase in prefrontal cortex glutamate; the increase remained significant in haloperidol-pretreated animals with no significant difference from vehicle group",
            "quantitative_details": "Haloperidol group: n=9, F=5.51, p<0.001; between-group comparison: F=0.88, p=0.59"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "2a4830b1-2645-403b-a778-bc0fbd14d037",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p4-s4"
              },
              {
                "source_element_id": "d9-p4-s5"
              },
              {
                "source_element_id": "d9-p4-s6"
              }
            ],
            "method_reference": "e2e61a2e-613e-4b77-8653-eae1a1d90045",
            "observation_type": "experimental outcome",
            "observation_summary": "M100907 pretreatment (0.1 mg/kg, IP) did not significantly block PCP-induced glutamate release; there was no significant difference between vehicle and M100907 pretreated groups",
            "quantitative_details": "M100907 group: n=7, increase did not reach significance; between-group comparison: F=0.28, p=0.99"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "9b0b6453-fc9f-4482-83d9-775b27a974c6",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s1"
              },
              {
                "source_element_id": "d9-p1-s2"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "measurement",
            "observation_summary": "Basal extracellular dopamine levels in the prefrontal cortex were 0.33 Â± 0.03 fmol/L (n=13)",
            "quantitative_details": "0.33 Â± 0.03 fmol/L, n=13"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "165bfdb0-2a02-467f-881e-9ad78ac01df2",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s8"
              },
              {
                "source_element_id": "d9-p1-s9"
              },
              {
                "source_element_id": "d9-p1-s10"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "measurement",
            "observation_summary": "Basal extracellular dopamine levels in the nucleus accumbens were 0.96 Â± 0.12 fmol/L (n=16)",
            "quantitative_details": "0.96 Â± 0.12 fmol/L, n=16"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "6c418e92-f7f4-4bef-a752-38270569e93b",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s1"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP produced a significant increase in stereotypy in vehicle-pretreated animals",
            "quantitative_details": "n=8, F=10, p<0.001"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "610f721a-5fba-464f-979f-9ad0886b6403",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s2"
              },
              {
                "source_element_id": "d9-p5-s3"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "M100907 pretreatment did not block PCP-induced increase in locomotion; there was no significant difference between vehicle and M100907 groups",
            "quantitative_details": "M100907 group: n=10, F=3.84, p<0.001; no significant difference between groups"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "a9856c7a-0877-46e2-bdff-1bbacb8c2015",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s2"
              },
              {
                "source_element_id": "d9-p5-s3"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "M100907 pretreatment did not block PCP-induced increase in stereotypy; there was no significant difference between vehicle and M100907 groups",
            "quantitative_details": "M100907 group: n=10, F=10, p<0.001; no significant difference between groups"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "0e8b6451-37b7-4dd0-9a1f-cdc75a989bb6",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s4"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP produced a robust significant increase in dopamine release in the prefrontal cortex in vehicle-pretreated animals",
            "quantitative_details": "n=6, F=17.7, p<0.001"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "4e2020c2-adb8-4b53-b7f5-605b6faf0349",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s4"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP produced a smaller but significant increase in dopamine release in the nucleus accumbens in vehicle-pretreated animals",
            "quantitative_details": "n=8, F=14.1, p<0.001"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "747eb82b-d3d2-4ba7-879e-6cbc4fa7815e",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s5"
              },
              {
                "source_element_id": "d9-p5-s6"
              },
              {
                "source_element_id": "d9-p5-s7"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "M100907 pretreatment did not block PCP-induced dopamine release in the prefrontal cortex; the increase remained significant with no significant difference from vehicle group",
            "quantitative_details": "M100907 group: n=7, F=5.8, p<0.001; between-group comparison: F=0.56, p=0.84"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "f52e4691-5479-4a76-a08c-95d8b0c31c7b",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s5"
              },
              {
                "source_element_id": "d9-p5-s8"
              },
              {
                "source_element_id": "d9-p5-s9"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "M100907 pretreatment did not block PCP-induced dopamine release in the nucleus accumbens; the increase remained significant with no significant difference from vehicle group",
            "quantitative_details": "M100907 group: n=8, F=6.9, p<0.001; between-group comparison: F=0.81, p=0.62"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "7cef0e5c-ca4b-4229-8895-7f6c12499bf7",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p1-s5"
              },
              {
                "source_element_id": "d9-p1-s6"
              },
              {
                "source_element_id": "d9-p1-s7"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "measurement",
            "observation_summary": "Basal extracellular serotonin levels in the prefrontal cortex were 0.30 Â± 0.02 fmol/L (n=6)",
            "quantitative_details": "0.30 Â± 0.02 fmol/L, n=6"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "39374905-c2d0-4115-b0ae-2b95152bdd66",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p2-s1"
              },
              {
                "source_element_id": "d9-p2-s2"
              },
              {
                "source_element_id": "d9-p2-s3"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP (5 mg/kg, IP) produced a significant increase in extracellular serotonin levels in the prefrontal cortex, quickly reaching a maximal level of 230% above baseline within 20 minutes post-injection and remaining elevated through experiment termination",
            "quantitative_details": "n=6, F=3.92, p<0.001; maximal level 230% above baseline at 20 min"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "59f60eb1-9d61-4c05-a249-61f2a29bf0e4",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d9-p5-s1"
              }
            ],
            "method_reference": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
            "observation_type": "experimental outcome",
            "observation_summary": "PCP produced a significant increase in locomotion in vehicle-pretreated animals",
            "quantitative_details": "n=8, F=3.49, p<0.001"
          },
          "created_at": "2025-11-26T12:32:32.384826Z"
        },
        {
          "id": "3bc43bc3-e272-491f-9888-483770526ba7",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "experimental outcome",
            "observation_summary": "Several genes showed significant expression changes after lithium treatment in bipolar disorder patients.",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "87302d53-2ea3-454f-b47d-e3feea954ca4",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "experimental outcome",
            "observation_summary": "14 gene pathways were identified in the integration analysis of lithium treatment effects.",
            "quantitative_details": "14 pathways"
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "2e92f5fc-2b11-4924-8fe9-2f5e8608ecb0",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "statistical result",
            "observation_summary": "Gray matter fraction showed significant increases after 8 weeks of lithium treatment in bipolar disorder patients compared to baseline.",
            "quantitative_details": "corrected p < 0.05"
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "6fa6ca37-84be-442f-8a02-bcd62668b4a1",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "statistical result",
            "observation_summary": "Global cortical thickness showed significant increases after 8 weeks of lithium treatment in bipolar disorder patients compared to baseline.",
            "quantitative_details": "corrected p < 0.05"
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "63a4961b-6367-4385-8097-d94448d68575",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "statistical result",
            "observation_summary": "The frontal cortex showed significant thickness increases after 8 weeks of lithium treatment in bipolar disorder patients compared to baseline.",
            "quantitative_details": "corrected p < 0.05"
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "8cef6180-9d5b-4d9c-9828-339e6895db16",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "statistical result",
            "observation_summary": "The parietal cortex showed significant thickness increases after 8 weeks of lithium treatment in bipolar disorder patients compared to baseline.",
            "quantitative_details": "corrected p < 0.05"
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "c574f9b8-37f0-4f49-a789-725e7f185e44",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "measurement",
            "observation_summary": "Putamen volume showed increases after 8 weeks of lithium treatment in bipolar disorder patients compared to baseline.",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "4de1dbc8-718d-4a8b-ac67-18d6cf16538f",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "measurement",
            "observation_summary": "Hippocampus volume showed increases after 8 weeks of lithium treatment in bipolar disorder patients compared to baseline.",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "810225b0-afa6-4a0d-8e0f-4659da7617f4",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "measurement",
            "observation_summary": "Thalamic nuclei volume showed increases after 8 weeks of lithium treatment in bipolar disorder patients compared to baseline.",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "23c5558b-8341-4efa-bc34-6c8f1000d668",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
            "observation_type": "measurement",
            "observation_summary": "Thalamic substructures volume showed increases after 8 weeks of lithium treatment in bipolar disorder patients compared to baseline.",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "463561d1-4913-4a97-864f-a039de9149ab",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s7"
              }
            ],
            "method_reference": "12b135c6-42ef-4c3d-853e-8e166dde9037",
            "observation_type": "statistical result",
            "observation_summary": "Nine gene pathways showed significant correlations with structural brain changes after lithium treatment.",
            "quantitative_details": "FDR < 0.05; 9 out of 14 pathways"
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "fe9bcd7d-67ee-45b4-92b6-0fc2ff136da3",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s8"
              }
            ],
            "method_reference": "12b135c6-42ef-4c3d-853e-8e166dde9037",
            "observation_type": "statistical result",
            "observation_summary": "Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) showed correlations with structural changes in multiple brain regions.",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "08a02331-0a05-478b-9a6e-64aba5885eb8",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s9"
              }
            ],
            "method_reference": "12b135c6-42ef-4c3d-853e-8e166dde9037",
            "observation_type": "statistical result",
            "observation_summary": "The sphingomyelin metabolism pathway showed association with HAM-D symptom change after lithium treatment.",
            "quantitative_details": "p < 0.01"
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "0ae633fd-1cf4-4289-8667-3af49e18773b",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s9"
              }
            ],
            "method_reference": "12b135c6-42ef-4c3d-853e-8e166dde9037",
            "observation_type": "statistical result",
            "observation_summary": "The effect of sphingomyelin metabolism pathway on HAM-D change is mediated via the volume of mediodorsal thalamus.",
            "quantitative_details": "p < 0.03"
          },
          "created_at": "2025-11-26T12:26:11.889430Z"
        },
        {
          "id": "0e285c05-eea2-4c95-857c-e494f2c29e99",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d13-p1-s3"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "Lithium exposure significantly affected 1051 genes at the gene level (FDR <0.05), with 669 up-regulated and 382 down-regulated",
            "quantitative_details": "1051 significant genes (FDR <0.05), 669 up-regulated, 382 down-regulated"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "4d7bc9c1-97c4-4257-b37f-cf333847f119",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d12-p1-s2"
              },
              {
                "source_element_id": "d12-p1-s3"
              },
              {
                "source_element_id": "d12-p1-s4"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "measurement",
            "observation_summary": "Serum lithium levels in all treated rats after 4 days of treatment were between 0.6-1.0 mmol/L (mean=0.725, sd=0.175)",
            "quantitative_details": "Serum lithium concentration range: 0.6-1.0 mmol/L, mean=0.725 mmol/L, sd=0.175 mmol/L"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "859f0c84-6012-4690-a23b-c74feff2bae2",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d12-p2-s3"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "measurement",
            "observation_summary": "Cell type composition in corpus callosum tissue showed oligodendrocytes as the most predominant cell type at approximately 55%, followed by astrocytes at approximately 25%",
            "quantitative_details": "Oligodendrocytes: ~55%, Astrocytes: ~25%"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "c56c361a-4b4d-41da-80aa-54db9bda14bb",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d12-p2-s5"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "There were no significant differences in cell type proportions between lithium-treated and untreated rats for any of the assessed cell types",
            "quantitative_details": "Two-sample t-tests showed no significant differences"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "501c4e17-45be-45eb-9381-d19703a1eb73",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d12-p3-s1"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "Principal component analysis of expressed genes showed clear but incomplete clustering by treatment condition along the two first principal components, explaining 46% of the total variance",
            "quantitative_details": "PC1 and PC2 explained 46% of total variance"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "4100050d-fbec-4a8b-b658-86b504e76fdc",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d13-p1-s4"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "measurement",
            "observation_summary": "The majority of lithium-affected genes were protein coding at 93%",
            "quantitative_details": "93% protein coding genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "3f12f878-f51f-4eca-b9ce-6fde0c46f1c3",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d13-p1-s5"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "measurement",
            "observation_summary": "Effect sizes (fold changes) for differentially expressed genes ranged from 0.31 to 3.27",
            "quantitative_details": "Fold change range: 0.31-3.27"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "7cee6240-87d4-4d81-970f-73c2c799cb15",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d13-p1-s6"
              },
              {
                "source_element_id": "d13-p1-s7"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "ATP14 was the most down-regulated protein coding gene with a fold change of 0.40 (p=7.07e-4)",
            "quantitative_details": "fc=0.40, p=7.07e-4"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "13e26b92-7ed6-4232-82e5-e95524063e53",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d13-p1-s7"
              },
              {
                "source_element_id": "d13-p1-s8"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "GPR101 was the most up-regulated gene with a fold change of 3.27 (p=3.66e-4)",
            "quantitative_details": "fc=3.27, p=3.66e-4"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "efddc6a9-a6eb-4b75-ac9f-72eeb6fc95dc",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d15-p1-s2"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "Pathway analysis identified 26 pathways that were significantly enriched by lithium exposure in the rat corpus callosum",
            "quantitative_details": "26 significantly enriched pathways"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "cda55c22-fdcd-4dc9-b3e2-89398896a004",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d15-p1-s3"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "qualitative finding",
            "observation_summary": "The primary effects of lithium were related to signal transduction and immunological functions, with additional effects on nervous system and cellular community processes",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "5695f5d2-343a-4ee7-a926-eaa30634a2ef",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d15-p1-s4"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "qualitative finding",
            "observation_summary": "Most of the significantly enriched pathways were activated (up-regulated) by lithium",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "7af17ca4-db3e-41dc-8ecb-594a2d675d32",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d16-p1-s4"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "Differential transcript expression analysis using RSEM identified 792 differentially expressed genes",
            "quantitative_details": "792 differentially expressed genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "0a889716-b45d-4d37-becc-94b3348e30b4",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d16-p1-s4"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "Differential transcript expression analysis using Salmon identified 684 differentially expressed genes",
            "quantitative_details": "684 differentially expressed genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "9241a89f-47b7-42cd-8e91-e1e6408ad9ad",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d16-p1-s5"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "There was a high degree of overlap between RSEM and Salmon transcript analyses with 487 DTE genes shared between the two tools",
            "quantitative_details": "487 overlapping DTE genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "fc047bb1-67b7-402f-8e38-0e20edf70106",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d16-p1-s6"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "Of the 487 significant DTE genes, 430 (88.3%) were also identified in the gene-level DGE analysis with similar p-values and fold changes",
            "quantitative_details": "430 out of 487 genes (88.3%) shared between DTE and DGE"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "5f875309-1d75-4f4c-9e5e-f4e69b4b7093",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d16-p1-s8"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "The DTE analysis identified 57 genes (33 up-regulated and 24 down-regulated) that were not detected in the DGE analysis",
            "quantitative_details": "57 DTE-only genes: 33 up-regulated, 24 down-regulated"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "9bbeda0c-3cfc-4bf6-a453-b1be4e8e139f",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d16-p1-s9"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "The DTE-only genes were enriched for GO terms related to neuronal processes",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "a6b83d4f-4a41-4fb7-b96e-5df689a30b87",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d17-p1-s2"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "Comparing the full set of lithium-associated genes (n=1108) with genes from 18 previous transcriptomic reports showed overlap with 112 genes (10.1%)",
            "quantitative_details": "112 overlapping genes (10.1%)"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "024721e4-d744-415b-8bed-1f9ebc713d3f",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d17-p1-s3"
              },
              {
                "source_element_id": "d17-p1-s4"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "The 112 overlapping genes with previous studies were enriched for biological processes related to cytoplasmic protein translation",
            "quantitative_details": "p=1.29e-5, fc=9.00"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "a56db633-14bc-4a57-9124-fba86cc18e6b",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              }
            ],
            "method_reference": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
            "observation_type": "statistical result",
            "observation_summary": "Lithium exposure significantly affected 1108 genes in total (combining gene and transcript-level analyses) at FDR <0.05, with 702 up-regulated and 406 down-regulated",
            "quantitative_details": "1108 genes (FDR <0.05), 702 up-regulated, 406 down-regulated"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "eda36acb-f9d0-48fb-a75f-14faddb4ed4e",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s2"
              }
            ],
            "method_reference": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
            "observation_type": "statistical result",
            "observation_summary": "eQTL analysis in Braineac database identified 272 eQTL genes associated with BD-associated lead SNPs",
            "quantitative_details": "272 eQTL genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "4c4762b3-81c6-4bc1-864d-d83d1f5eca9a",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s2"
              }
            ],
            "method_reference": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
            "observation_type": "statistical result",
            "observation_summary": "eQTL analysis in gTEX database identified 18 eQTL genes associated with BD-associated lead SNPs",
            "quantitative_details": "18 eQTL genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "7ace3855-d37b-4487-8adb-924dabcf671e",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s2"
              }
            ],
            "method_reference": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
            "observation_type": "statistical result",
            "observation_summary": "eQTL analysis in CMC database identified 48 eQTL genes associated with BD-associated lead SNPs",
            "quantitative_details": "48 eQTL genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "5644b0be-7c17-418d-8fa0-906b710e68aa",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s3"
              }
            ],
            "method_reference": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
            "observation_type": "statistical result",
            "observation_summary": "No eQTL gene was identified by all three databases",
            "quantitative_details": "0 genes shared across all three databases"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "3eb1a492-e1d7-4b8e-bb3c-9a43c204ae45",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s3"
              }
            ],
            "method_reference": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
            "observation_type": "statistical result",
            "observation_summary": "18 genes were shared between Braineac and CMC databases",
            "quantitative_details": "18 shared genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "888bac4c-adac-47f5-ac42-67ac5d7f75c4",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s3"
              }
            ],
            "method_reference": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
            "observation_type": "statistical result",
            "observation_summary": "6 genes were shared between Braineac and gTEX databases",
            "quantitative_details": "6 shared genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "bca89b7b-9ad8-450f-891b-5147d855732f",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s3"
              }
            ],
            "method_reference": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
            "observation_type": "statistical result",
            "observation_summary": "7 genes were shared between gTEX and CMC databases",
            "quantitative_details": "7 shared genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "773c233f-204f-4d18-8e65-30a1e7bf6f64",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s4"
              },
              {
                "source_element_id": "abs-d1-p1-s9"
              }
            ],
            "method_reference": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
            "observation_type": "statistical result",
            "observation_summary": "Of the 307 unique eQTL genes identified in total across all three databases, 12 overlapped with lithium-associated genes from the rat study",
            "quantitative_details": "307 unique eQTL genes, 12 overlapping with lithium-associated genes"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "3a77ca43-4121-40b2-a118-6b708455b4fe",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s6"
              },
              {
                "source_element_id": "abs-d1-p1-s10"
              },
              {
                "source_element_id": "abs-d1-p1-s11"
              }
            ],
            "method_reference": "87bf24e0-ca0f-40b8-a9a7-21db12bbd1e2",
            "observation_type": "statistical result",
            "observation_summary": "RPS23 gene was significantly down-regulated in BD cases compared to healthy controls (p=0.0036), with 20% reduced expression",
            "quantitative_details": "p=0.0036, fc=0.80 (20% reduction)"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "e5710b87-b505-444f-a0f9-fc3e0debb92e",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s8"
              },
              {
                "source_element_id": "abs-d1-p1-s11"
              },
              {
                "source_element_id": "abs-d1-p1-s12"
              }
            ],
            "method_reference": "87bf24e0-ca0f-40b8-a9a7-21db12bbd1e2",
            "observation_type": "statistical result",
            "observation_summary": "GRIN2A showed suggestive evidence of down-regulation in BD cases compared to healthy controls (p=0.056), with 35% reduction in expression levels",
            "quantitative_details": "p=0.056, fc=0.65 (35% reduction)"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "323ac5ee-20ae-4f97-b07e-739ed0f2754f",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d18-p1-s9"
              },
              {
                "source_element_id": "d18-p1-s10"
              },
              {
                "source_element_id": "abs-d1-p1-s13"
              },
              {
                "source_element_id": "abs-d1-p1-s14"
              }
            ],
            "method_reference": "87bf24e0-ca0f-40b8-a9a7-21db12bbd1e2",
            "observation_type": "statistical result",
            "observation_summary": "GRIN2A expression was significantly up-regulated by lithium in rat brains (p=2.2e-5, fc=1.6), which is in the opposite direction to its down-regulation observed in BD patients",
            "quantitative_details": "p=2.2e-5, fc=1.6"
          },
          "created_at": "2025-11-26T12:30:50.813091Z"
        },
        {
          "id": "588228d1-308e-4d9d-b269-c886c77e47aa",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p5-s7"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical measurement",
            "observation_summary": "High-molecular-mass AÎ² assemblies (>20 kDa) appear in mice older than 6 months",
            "quantitative_details": "Molecular mass threshold: >20 kDa"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "466670f2-3511-49ec-8dda-e5937401f3cb",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p1-s4"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "behavioral finding",
            "observation_summary": "Young Tg2576 mice (<6 months old) have normal memory and lack neuropathology",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "43144685-5d9b-4f8c-a0f5-e8c8c78d020e",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p1-s4"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "behavioral finding",
            "observation_summary": "Middle-aged Tg2576 mice (6-14 months old) develop memory deficits without neuronal loss",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "0a4e57ad-26b0-4418-a578-f66b2302f5fb",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p1-s4"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "neuropathological finding",
            "observation_summary": "Old Tg2576 mice (>14 months old) form abundant neuritic plaques containing amyloid-Î²",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "0cd17033-add3-42ea-8bca-6ea05496319c",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p3-s3"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "behavioral finding",
            "observation_summary": "Spatial reference memory in Tg2576 mice declines modestly but significantly at 6 months of age and then remains stable for 7 to 8 months",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "937c82f2-d7a2-4ab1-aeca-890360ce4e35",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p5-s5"
              },
              {
                "source_element_id": "d1-p5-s6"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical measurement",
            "observation_summary": "A set of apparent assemblies of AÎ² were detected in the soluble, extracellular-enriched fraction from 6-month-old mice, including bands at molecular masses corresponding to trimeric (14 kDa), hexameric (27 kDa), nonameric (40 kDa) and dodecameric (56 kDa) AÎ²1-42 assemblies",
            "quantitative_details": "Molecular masses: 14 kDa, 27 kDa, 40 kDa, 56 kDa"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "5b256c21-dfa7-46f4-8a8d-b5d4b9b07f16",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p6-s4"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical finding",
            "observation_summary": "AÎ² oligomers were unaltered in SDS-PAGE containing 8 M urea",
            "quantitative_details": "8 M urea concentration"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "f3ccd383-f0cd-4223-98b8-f46c5b86afb3",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p6-s5"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical finding",
            "observation_summary": "When exposed to â¥10% hexafluoroisopropanol (HFIP), the theoretical hexamers, nonamers and dodecamers depolymerized, with a parallel increase in levels of tetramers, trimers and monomers",
            "quantitative_details": "â¥10% HFIP concentration"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "c488ef10-8d0f-4eca-a2f5-2b298b98d5ed",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p6-s6"
              },
              {
                "source_element_id": "d1-p6-s7"
              },
              {
                "source_element_id": "d1-p6-s8"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical finding",
            "observation_summary": "In >20% HFIP, only the putative trimers remained; these dissociated into AÎ² monomers in >55% HFIP",
            "quantitative_details": ">20% HFIP for trimer retention; >55% HFIP for monomer dissociation"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "c437dd95-494e-4583-b9ae-7f0a56b30c97",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p6-s11"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "immunochemical finding",
            "observation_summary": "A11 antiserum detected only 27-56 kDa complexes in extracellular-enriched extracts",
            "quantitative_details": "Molecular mass range: 27-56 kDa"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "c5999cbc-a7c2-4a93-8c56-157cb9a90088",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p6-s15"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical finding",
            "observation_summary": "High- and low-molecular-mass AÎ² assemblies were collected in different fractions during non-denaturing size-exclusion chromatography",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "e4506fe8-3fc1-4ce1-a61b-35cb9f35c51e",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p7-s2"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical measurement",
            "observation_summary": "A 56-kDa band appeared in extracts at 6 months of age, along with lesser quantities of a 40-kDa species",
            "quantitative_details": "Molecular masses: 56 kDa and 40 kDa"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "ca4752c1-18e6-4da3-b7f7-c6d5adf3c097",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p8-s1"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical measurement",
            "observation_summary": "The mean levels of the soluble AÎ² assemblies remained stable after 6 months of age, although there was considerable variability between animals of the same age",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "b6646bec-b09b-44dc-a9f7-37fff9956cf7",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p8-s3"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical finding",
            "observation_summary": "There was no further increase in AÎ² assemblies in old mice to correspond to the second drop in memory function at 15 months",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "5796d922-5a0c-4438-8a6e-9bc8e61563fc",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p9-s3"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "statistical result",
            "observation_summary": "Monomers, trimers and hexamers of AÎ² did not correlate significantly with performance in 5- or 6-month-old mice",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "d8c075bc-30ba-40d2-857c-31ae4d6d48a5",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p9-s4"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "statistical result",
            "observation_summary": "Significant inverse relationships were observed between the levels of 56-kDa and 40-kDa assemblies and memory performance",
            "quantitative_details": "rÂ² = 0.66 for 56-kDa assembly; rÂ² = 0.45 for 40-kDa assembly"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "5b453820-679e-450e-8fef-08cce8387fb6",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p9-s5"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "statistical result",
            "observation_summary": "There were no correlations between the levels of any AÎ² oligomers and performance in the cued phase of a water maze test",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "fc2de9af-d713-400d-8e4d-699039a95bbf",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p10-s2"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical finding",
            "observation_summary": "Only trimeric and monomeric AÎ² species were detected in the soluble, intracellular-enriched fraction, with no modulation between 5 and 6 months of age",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "1a714347-37dc-4979-9df1-5f5fe261cb99",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p10-s3"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical finding",
            "observation_summary": "There was no change in the levels of APP, CTF-Î²s or CTF-Î± in membrane-associated fractions",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "2e141677-01bc-4a8a-a9c1-033f5164f86b",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p10-s4"
              }
            ],
            "method_reference": "c0385795-90d3-4532-9275-b829e10b36c4",
            "observation_type": "biochemical finding",
            "observation_summary": "In cytosolic extracts of primary Tg2576 cortical neurons cultured from 14-15-day-old embryos, monomers and trimers were the only AÎ² species detected",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "c09be0ec-a026-4089-9d3d-236aa0d4881b",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p14-s4"
              }
            ],
            "method_reference": "519e1d37-f5eb-422f-a17c-cdc0736d069b",
            "observation_type": "behavioral finding",
            "observation_summary": "Infusing 10 Î¼l of 0.85 mM AÎ²*56 two hours before testing had no effect on the escape latencies of rats given eight training trials to locate a hidden platform",
            "quantitative_details": "10 Î¼l volume; 0.85 mM concentration"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "cc106d3f-f91c-4f89-b69b-740d1e51d358",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p15-s3"
              }
            ],
            "method_reference": "519e1d37-f5eb-422f-a17c-cdc0736d069b",
            "observation_type": "statistical result",
            "observation_summary": "There was a significant interaction of group Ã quadrant (F1,18 = 6.288, P = 0.022, ANOVA), but no main effects of group or quadrant",
            "quantitative_details": "F1,18 = 6.288, P = 0.022"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "2229baac-6b91-46f1-83b0-aebc11cc7b73",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p15-s4"
              }
            ],
            "method_reference": "519e1d37-f5eb-422f-a17c-cdc0736d069b",
            "observation_type": "statistical result",
            "observation_summary": "Rats in the vehicle group spent significantly more time in a target annulus surrounding the platform than in a control annulus in the opposite quadrant (t9 = 2.668, P = 0.026)",
            "quantitative_details": "t9 = 2.668, P = 0.026"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "3dfa9500-4691-4807-ba04-262475571d13",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p15-s5"
              }
            ],
            "method_reference": "519e1d37-f5eb-422f-a17c-cdc0736d069b",
            "observation_type": "statistical result",
            "observation_summary": "Rats in the AÎ²*56 group spent similar amounts of time in both the target and control annuli (P = 0.547)",
            "quantitative_details": "P = 0.547"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "5c789b4a-4174-4660-854d-4e5baa60cc21",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p15-s6"
              }
            ],
            "method_reference": "519e1d37-f5eb-422f-a17c-cdc0736d069b",
            "observation_type": "statistical result",
            "observation_summary": "Rats in the AÎ²*56 group spent significantly less time in the target annulus than those in the vehicle group (t18 = 2.533, P = 0.021)",
            "quantitative_details": "t18 = 2.533, P = 0.021"
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "abbf8ffe-b71f-48db-9ef5-a072f7abf0bf",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p18-s5"
              }
            ],
            "method_reference": "519e1d37-f5eb-422f-a17c-cdc0736d069b",
            "observation_type": "behavioral finding",
            "observation_summary": "AÎ²*56 had no effect on escape latencies to a visible platform",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "d8774afa-4b5b-493b-a22c-bcf207ac45ef",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d1-p18-s3"
              }
            ],
            "method_reference": "519e1d37-f5eb-422f-a17c-cdc0736d069b",
            "observation_type": "behavioral finding",
            "observation_summary": "Ten days after the test with AÎ²*56, both groups had equally good acquisition and retention in the same two-day protocol when new spatial information was provided but no AÎ²*56 was administered",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T11:17:12.902726Z"
        },
        {
          "id": "d7f534ce-14cc-4915-a6bf-1340924d47ec",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              }
            ],
            "method_reference": "9c31dcdc-f814-44b0-aaca-3fe6364aabe5",
            "observation_type": "experimental outcome",
            "observation_summary": "The PKC activator phorbol 12-myristate 13-acetate (PMA) induced an antidepressant-like effect in the forced swim test in rats",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "541670e8-5e38-41f9-85c1-dab5e6a8391f",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "111f61c1-05bf-4803-9454-c031a6d08406",
            "observation_type": "experimental outcome",
            "observation_summary": "A single injection of tamoxifen (80 mg/kg, i.p.) attenuated amphetamine-induced hyperlocomotion in rats",
            "quantitative_details": "80 mg/kg, i.p."
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "9cf73253-3a2a-404f-b033-ae3a6b249bd9",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "111f61c1-05bf-4803-9454-c031a6d08406",
            "observation_type": "experimental outcome",
            "observation_summary": "A single injection of chelerythrine (3 mg/kg, s.c.) attenuated amphetamine-induced hyperlocomotion in rats",
            "quantitative_details": "3 mg/kg, s.c."
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "26b8a6b4-01f1-4493-ad22-9a748702bb1f",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "4741ff9e-5b7a-4dc9-89b6-c98eb62a1d73",
            "observation_type": "experimental outcome",
            "observation_summary": "A single injection of tamoxifen (80 mg/kg, i.p.) decreased risk-taking behavior in rats",
            "quantitative_details": "80 mg/kg, i.p."
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "9b8d33db-d4f8-4cbc-9dda-1901b21a0afd",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "4741ff9e-5b7a-4dc9-89b6-c98eb62a1d73",
            "observation_type": "experimental outcome",
            "observation_summary": "A single injection of chelerythrine (3 mg/kg, s.c.) decreased risk-taking behavior in rats",
            "quantitative_details": "3 mg/kg, s.c."
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "e09855d2-0430-488b-b6d8-d3cc6c56940d",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "9c31dcdc-f814-44b0-aaca-3fe6364aabe5",
            "observation_type": "experimental outcome",
            "observation_summary": "Chronic exposure to tamoxifen (10 mg/kg/day, i.p., for 14 days) caused depressive-like behavior in the forced swim test in rats",
            "quantitative_details": "10 mg/kg/day, i.p., for 14 days"
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "b79f1d04-7da4-497d-856c-ed7e6908f239",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "9c31dcdc-f814-44b0-aaca-3fe6364aabe5",
            "observation_type": "experimental outcome",
            "observation_summary": "Chronic exposure to chelerythrine (0.3 mg/kg/day, s.c., for 14 days) caused depressive-like behavior in the forced swim test in rats",
            "quantitative_details": "0.3 mg/kg/day, s.c., for 14 days"
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "88f5e6ef-b876-4ed0-87d6-877828b17730",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "a084af9e-8a41-4a18-992f-cb561f86e62c",
            "observation_type": "experimental outcome",
            "observation_summary": "Chronic exposure to tamoxifen (10 mg/kg/day, i.p., for 14 days) resulted in a reduction of cell proliferation in the dentate gyrus of the hippocampus in rats",
            "quantitative_details": "10 mg/kg/day, i.p., for 14 days"
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "e984734a-ef45-40ba-b127-4d6926e46e04",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "a084af9e-8a41-4a18-992f-cb561f86e62c",
            "observation_type": "experimental outcome",
            "observation_summary": "Chronic exposure to chelerythrine (0.3 mg/kg/day, s.c., for 14 days) resulted in a reduction of cell proliferation in the dentate gyrus of the hippocampus in rats",
            "quantitative_details": "0.3 mg/kg/day, s.c., for 14 days"
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "d9724839-2fb7-4f8e-8617-4d33eba64514",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              }
            ],
            "method_reference": "4741ff9e-5b7a-4dc9-89b6-c98eb62a1d73",
            "observation_type": "experimental outcome",
            "observation_summary": "The PKC activator phorbol 12-myristate 13-acetate (PMA) enhanced risk-taking behavior in rats",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T13:10:03.686417Z"
        },
        {
          "id": "1b746c0f-6ef0-4715-a468-2461475844d9",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "3d4db5bc-9305-45d0-b5e1-bc1db954dd2a",
            "observation_type": "experimental outcome",
            "observation_summary": "A single injection of the PKC inhibitor tamoxifen (80 mg/kg, i.p.) attenuated amphetamine-induced hyperlocomotion in rats",
            "quantitative_details": "Tamoxifen dose: 80 mg/kg i.p."
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "1caf7294-cd8d-48c9-aa95-a1d7e4dcec38",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "3d4db5bc-9305-45d0-b5e1-bc1db954dd2a",
            "observation_type": "experimental outcome",
            "observation_summary": "A single injection of the PKC inhibitor chelerythrine (3 mg/kg, s.c.) attenuated amphetamine-induced hyperlocomotion in rats",
            "quantitative_details": "Chelerythrine dose: 3 mg/kg s.c."
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "4fe70e90-8f98-45b9-a73c-2fd36d7e6207",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "c25ffd4a-2681-4f96-815f-90b4eb142477",
            "observation_type": "experimental outcome",
            "observation_summary": "A single injection of the PKC inhibitor tamoxifen (80 mg/kg, i.p.) decreased risk-taking behavior in rats",
            "quantitative_details": "Tamoxifen dose: 80 mg/kg i.p."
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "217e973c-565e-440e-a7b8-0084352e4493",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              }
            ],
            "method_reference": "c25ffd4a-2681-4f96-815f-90b4eb142477",
            "observation_type": "experimental outcome",
            "observation_summary": "A single injection of the PKC inhibitor chelerythrine (3 mg/kg, s.c.) decreased risk-taking behavior in rats",
            "quantitative_details": "Chelerythrine dose: 3 mg/kg s.c."
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "aa4877e3-5631-4bbd-87f6-e54165258a81",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              }
            ],
            "method_reference": "c25ffd4a-2681-4f96-815f-90b4eb142477",
            "observation_type": "experimental outcome",
            "observation_summary": "The PKC activator phorbol 12-myristate 13-acetate (PMA) enhanced risk-taking behavior in rats",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "79cd731c-1206-4741-ad04-d6e89ad5c4b4",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "753af1d3-0b73-4135-8629-6770fe6877c0",
            "observation_type": "experimental outcome",
            "observation_summary": "Chronic exposure to tamoxifen (10 mg/kg/day, i.p., for 14 days) caused depressive-like behavior in the forced swim test in rats",
            "quantitative_details": "Tamoxifen: 10 mg/kg/day i.p. for 14 days"
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "bbe63b7c-ca93-4ee3-bdaa-6ed15d495322",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "753af1d3-0b73-4135-8629-6770fe6877c0",
            "observation_type": "experimental outcome",
            "observation_summary": "Chronic exposure to chelerythrine (0.3 mg/kg/day, s.c., for 14 days) caused depressive-like behavior in the forced swim test in rats",
            "quantitative_details": "Chelerythrine: 0.3 mg/kg/day s.c. for 14 days"
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "5c8c48be-e7cd-4c17-96f5-c1cea389b4fd",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s6"
              }
            ],
            "method_reference": "753af1d3-0b73-4135-8629-6770fe6877c0",
            "observation_type": "experimental outcome",
            "observation_summary": "The PKC activator phorbol 12-myristate 13-acetate (PMA) induced an antidepressant-like effect in rats",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "2f40219a-fcfa-4b76-9839-a5d612ca2996",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "8b00dc4e-9d97-40d9-b62e-6dd5f0b05c62",
            "observation_type": "experimental outcome",
            "observation_summary": "Chronic exposure to tamoxifen (10 mg/kg/day, i.p., for 14 days) resulted in a reduction of cell proliferation in the dentate gyrus of the hippocampus in rats",
            "quantitative_details": "Tamoxifen: 10 mg/kg/day i.p. for 14 days"
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "bbbaf9da-deb7-44c1-b0ab-c0801280f8f5",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              }
            ],
            "method_reference": "8b00dc4e-9d97-40d9-b62e-6dd5f0b05c62",
            "observation_type": "experimental outcome",
            "observation_summary": "Chronic exposure to chelerythrine (0.3 mg/kg/day, s.c., for 14 days) resulted in a reduction of cell proliferation in the dentate gyrus of the hippocampus in rats",
            "quantitative_details": "Chelerythrine: 0.3 mg/kg/day s.c. for 14 days"
          },
          "created_at": "2025-11-26T12:33:24.465369Z"
        },
        {
          "id": "1eb5f478-6876-420b-93f5-adce65ce22eb",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p2-s2"
              }
            ],
            "method_reference": "c9c40336-98d5-4ed3-812c-88555959ddd7",
            "observation_type": "comparative clinical outcome",
            "observation_summary": "Response at 24 hours was greater with ketamine than with midazolam (active placebo control) in treatment-resistant depression",
            "quantitative_details": "24 h measurement timepoint"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "0dfe42c0-20bd-4f9c-a388-7c46b2c51130",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p2-s3"
              },
              {
                "source_element_id": "d3-p2-s4"
              }
            ],
            "method_reference": "40e2d5ed-d745-4428-83f5-d0bcaabbf1df",
            "observation_type": "sustained clinical outcome",
            "observation_summary": "27% of patients treated with a single intravenous dose of ketamine (0.5 mg/kg) maintained their antidepressant response 4 weeks post-treatment",
            "quantitative_details": "27% sustained response rate at 4 weeks, 0.5 mg/kg ketamine dose"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "45de8027-3e42-46b0-96bf-c388658ef992",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p1-s2"
              },
              {
                "source_element_id": "d3-p1-s3"
              }
            ],
            "method_reference": "ed8c34be-5a46-4fc3-b315-1563ba31d333",
            "observation_type": "clinical therapeutic outcome",
            "observation_summary": "Intravenous ketamine infusion (0.5 mg/kg over 40 min) evoked a robust and persistent antidepressant effect in 9 patients with treatment-resistant unipolar or bipolar depression after the disappearance of the initial psychotomimetic phase, with maximal effects observed at 72 hours post-infusion",
            "quantitative_details": "9 patients, 0.5 mg/kg ketamine dose, 40 min infusion, maximal effects at 72 h"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "20b4c1bf-1c35-4f6e-80d4-438c9c6591d4",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p1-s4"
              }
            ],
            "method_reference": "bda6137d-beff-40c7-bbe3-4db4275146b5",
            "observation_type": "clinical therapeutic outcome",
            "observation_summary": "Ketamine infusion evoked an antidepressant response in 71% of treatment-resistant depressive (TRD) unipolar and bipolar patients",
            "quantitative_details": "71% response rate"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "65723a06-fece-4379-a2c7-5edf633da02d",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p1-s5"
              }
            ],
            "method_reference": "bda6137d-beff-40c7-bbe3-4db4275146b5",
            "observation_type": "temporal clinical outcome",
            "observation_summary": "Significant improvement occurred as soon as 110 minutes after the beginning of ketamine infusion and remained for up to 7 days, with maximal antidepressant effects occurring after 24 hours of infusion",
            "quantitative_details": "Significant improvement at 110 min, maximal effects at 24 h, duration up to 7 days"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "0183ba53-8992-44ee-9f54-d1f39f1b2807",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p2-s5"
              }
            ],
            "method_reference": "1d989ce1-be8c-43ed-8699-b189ff099160",
            "observation_type": "clinical therapeutic outcome",
            "observation_summary": "Low-dose ketamine (0.2 mg/kg, i.v., infusion in 1-2 min) produced very robust reduction of severity in 14 emergency depressed patients with marked suicidal ideation",
            "quantitative_details": "14 patients, 0.2 mg/kg ketamine dose, 1-2 min infusion time"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "370de8fa-6468-4286-b7f4-5346d69bf925",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p3-s4"
              }
            ],
            "method_reference": "0ed59e18-395d-4153-9630-cd4ef25d3a6c",
            "observation_type": "temporal clinical outcome",
            "observation_summary": "Among responders to repeated ketamine infusions (up to six i.v. infusions, 3 times weekly over 12 days), the median time to relapse was 18 days",
            "quantitative_details": "Median time to relapse: 18 days, up to 6 infusions, 3 times weekly over 12 days"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "e8b1b074-8ba1-4c5f-852f-57c83cde4aa1",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p3-s5"
              }
            ],
            "method_reference": "0ed59e18-395d-4153-9630-cd4ef25d3a6c",
            "observation_type": "predictive clinical finding",
            "observation_summary": "The antidepressant response at 4 hours after ketamine infusion was highly predictive of a sustained response to subsequent infusions",
            "quantitative_details": "4 hr predictive timepoint"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "2c0bf822-817f-4a5d-9ad9-250b8667a1ac",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p4-s3"
              }
            ],
            "method_reference": "9f0de866-4b40-471b-9d85-3625790b7003",
            "observation_type": "clinical therapeutic outcome",
            "observation_summary": "Intranasal ketamine administration (single dose of 50 mg) evoked a significant improvement in depressive symptoms 24 hours after ketamine, compared to placebo",
            "quantitative_details": "50 mg intranasal dose, significant improvement at 24 h"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "af5fdbe3-d00d-4fb2-b318-550d2aa642d6",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p7-s3"
              }
            ],
            "method_reference": "e7afdb77-fc67-4b4c-88fc-f7d62e9a5a55",
            "observation_type": "comparative clinical outcome",
            "observation_summary": "Lanicemine (AZD6765), a low-affinity NMDA receptor antagonist, showed a comparable onset of antidepressant action yet a lower response rate than ketamine at 80 minutes post-administration",
            "quantitative_details": "80 min measurement timepoint, lower response rate than ketamine"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "0a79d1dd-2ffe-4b55-b7cb-e5a92dee0de0",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p7-s4"
              }
            ],
            "method_reference": "e7afdb77-fc67-4b4c-88fc-f7d62e9a5a55",
            "observation_type": "clinical side effect observation",
            "observation_summary": "Lanicemine lacked psychotomimetic action, suggesting that antidepressant effects are not associated with the psychotomimetic action",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "c03b4a3c-fd6c-453b-b892-de0bc60c4cc5",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p8-s3"
              }
            ],
            "method_reference": "cdcadac1-1649-4778-ae04-d01c76d4d42e",
            "observation_type": "biomarker finding",
            "observation_summary": "Pretreatment serine plasma concentrations were significantly lower in ketamine responder patients than in non-responders",
            "quantitative_details": "Significantly lower serine in responders vs non-responders"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "30a13429-ce9c-412f-bf23-f89c1f6c1e33",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p8-s4"
              }
            ],
            "method_reference": "cdcadac1-1649-4778-ae04-d01c76d4d42e",
            "observation_type": "biomarker finding",
            "observation_summary": "Serum vitamin B12 concentration was significantly higher in bipolar patients responding to ketamine",
            "quantitative_details": "Significantly higher vitamin B12 in ketamine responders"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "4ee1c4ce-1d7e-4cb1-9159-00521013655b",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p8-s4"
              }
            ],
            "method_reference": "cdcadac1-1649-4778-ae04-d01c76d4d42e",
            "observation_type": "null biomarker finding",
            "observation_summary": "No differences were found in the levels of homocysteine (a NMDA receptor agonist) in ketamine responders versus non-responders, despite the role of vitamin B12 in its metabolism",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "7dc60ed6-6847-4fe4-942e-db63c45b9ed2",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p9-s1"
              }
            ],
            "method_reference": "3007b5bc-5f5f-4e6e-9bab-fe448a8bc0a7",
            "observation_type": "neuroimaging biomarker finding",
            "observation_summary": "Magnetoencephalography revealed that increased activity in the anterior cingulate cortex in response to the presentation of affectively-charged stimuli predicted antidepressant response to ketamine",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "1d481df7-7085-4d09-a4b4-d79e70359da6",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p10-s2"
              }
            ],
            "method_reference": "f0b211b7-5301-419b-a999-279e74562db2",
            "observation_type": "biomarker finding",
            "observation_summary": "Ketamine significantly increased plasma BDNF levels in responder patients 240 minutes after infusion",
            "quantitative_details": "Significant increase at 240 min post-infusion in responders"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "59806c7f-1e1c-44d6-bd97-70873198be59",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p10-s4"
              }
            ],
            "method_reference": "f0b211b7-5301-419b-a999-279e74562db2",
            "observation_type": "genetic association finding",
            "observation_summary": "MDD patients with the Val/Val BDNF allele at rs6265 were more likely to exhibit enhanced antidepressant response to ketamine than Met carriers",
            "quantitative_details": "Val/Val genotype at rs6265 associated with better ketamine response vs Met carriers"
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        },
        {
          "id": "4bafb619-d557-4778-806e-c63b4e143e7b",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "observation",
          "content": {
            "source_elements": [
              {
                "source_element_id": "d3-p10-s5"
              }
            ],
            "method_reference": "f0b211b7-5301-419b-a999-279e74562db2",
            "observation_type": "biomarker and neurophysiological finding",
            "observation_summary": "Only patients responding to ketamine exhibited a simultaneous elevation of plasma BDNF levels and early slow wave activity (SWA), suggesting this effect may be associated with the rapid antidepressant effects of ketamine",
            "quantitative_details": null
          },
          "created_at": "2025-11-26T12:24:42.008308Z"
        }
      ],
      "methods": [
        {
          "id": "f8411335-d94d-43b2-acbf-22bec328a1ce",
          "paper_id": "10e6f40a-e864-4a66-9695-d93693e7a398",
          "job_id": "5ba77360-d0f0-462b-b734-48ca34a7467d",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "A polygenic score analysis testing the association between major depression genetic risk and lithium treatment response in bipolar disorder patients, using data from the International Consortium on Lithium Genetics (ConLi+Gen) with n=2586 patients.",
            "source_elements": [
              {
                "source_element_id": "d2-h1"
              },
              {
                "source_element_id": "d4-h1"
              },
              {
                "source_element_id": "d4-p1-s1"
              },
              {
                "source_element_id": "d4-p1-s2"
              },
              {
                "source_element_id": "d4-p1-s3"
              }
            ],
            "structured_method_description": {
              "study_subject": "Patients with bipolar disorder receiving lithium treatment (n=2586 from ConLi+Gen consortium)",
              "observed_outcomes": "Lithium treatment response in bipolar disorder patients",
              "manipulated_conditions": "Polygenic score for major depression (genetic risk variation)",
              "control_or_reference_point": "Baseline genetic risk levels or non-responders to lithium treatment (specific control structure not detailed in provided excerpt)",
              "study_design_or_method_class": "Genetic association study using polygenic risk scores"
            }
          },
          "created_at": "2025-11-26T12:28:42.879714Z"
        },
        {
          "id": "d17a7564-c957-4b98-b1d1-a1e538d03151",
          "paper_id": "174bc307-7fde-44a3-81f0-c4af3de84fe4",
          "job_id": "ece1f578-9d7e-4658-856c-481acf31b9bf",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Double-blind, randomized, placebo-controlled trial comparing lithium plus tamoxifen (80 mg/day) versus lithium plus placebo over 6 weeks in hospitalized patients with acute bipolar mania, with outcomes measured using the Young Mania Rating Scale.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s2"
              },
              {
                "source_element_id": "abs-d1-p1-s3"
              },
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "abs-d1-p1-s5"
              },
              {
                "source_element_id": "d5-p1-s1"
              },
              {
                "source_element_id": "d5-p1-s2"
              },
              {
                "source_element_id": "d5-p1-s3"
              },
              {
                "source_element_id": "d5-p1-s4"
              },
              {
                "source_element_id": "d5-p1-s5"
              },
              {
                "source_element_id": "d5-p1-s6"
              },
              {
                "source_element_id": "d5-p1-s7"
              }
            ],
            "structured_method_description": {
              "study_subject": "Hospitalized bipolar disorder patients (ages 19-49 years) experiencing acute manic episodes (n=40)",
              "observed_outcomes": "Manic symptom severity measured by Young Mania Rating Scale (YMRS) scores at baseline and at days 7, 14, 28, and 42; Positive and Negative Syndrome Scale (PANSS) total scores; side effect frequency",
              "manipulated_conditions": "Adjunctive treatment: tamoxifen (80 mg/day) versus placebo, both added to lithium therapy (1-1.2 mEq/L) for 6 weeks",
              "control_or_reference_point": "Lithium plus placebo group (standard lithium monotherapy)",
              "study_design_or_method_class": "Double-blind, randomized, placebo-controlled clinical trial"
            }
          },
          "created_at": "2025-11-26T12:26:35.104359Z"
        },
        {
          "id": "aafa5a4a-2370-4809-964b-420024e61a52",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological intervention study examining whether antipsychotic drugs (haloperidol, clozapine, or M100907) attenuate phencyclidine (PCP)-induced increases in glutamate efflux in the prefrontal cortex, measured via microdialysis in rats",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s3"
              },
              {
                "source_element_id": "d4-p1-s3"
              },
              {
                "source_element_id": "d4-p1-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Rats with microdialysis probes in prefrontal cortex",
              "observed_outcomes": "Glutamate efflux levels in prefrontal cortex measured by microdialysis with HPLC-fluorescence detection",
              "manipulated_conditions": "Pretreatment with vehicle, clozapine (10 mg/kg), haloperidol (0.1 mg/kg), or M100907 (0.1 mg/kg) followed by PCP (5 mg/kg) administration",
              "control_or_reference_point": "Vehicle pretreatment before PCP administration; baseline glutamate levels collected before drug administration",
              "study_design_or_method_class": "Pharmacological challenge study with microdialysis"
            }
          },
          "created_at": "2025-11-26T13:09:52.839604Z"
        },
        {
          "id": "c65963f2-80ee-4a7e-9fd7-add7ad73d6ed",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Pharmacological intervention study examining the effect of M100907 (5-HT2A antagonist) on PCP-induced dopamine release in cortex and nucleus accumbens, with concurrent behavioral measurements of locomotion and stereotypy",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "d4-p1-s7"
              }
            ],
            "structured_method_description": {
              "study_subject": "Rats with microdialysis probes in prefrontal cortex and nucleus accumbens",
              "observed_outcomes": "Dopamine efflux in cortex and nucleus accumbens measured by microdialysis with HPLC-electrochemical detection; locomotor activity and stereotypy behavior",
              "manipulated_conditions": "Pretreatment with M100907 or vehicle followed by PCP administration",
              "control_or_reference_point": "Vehicle pretreatment before PCP administration; baseline dopamine levels and baseline behavior",
              "study_design_or_method_class": "Pharmacological challenge study with microdialysis and behavioral assessment"
            }
          },
          "created_at": "2025-11-26T13:09:52.839604Z"
        },
        {
          "id": "e2e61a2e-613e-4b77-8653-eae1a1d90045",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological intervention study examining whether antipsychotic drugs (haloperidol, clozapine, or M100907) attenuate phencyclidine (PCP)-induced increases in glutamate efflux in the prefrontal cortex, measured via microdialysis in rats",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s3"
              },
              {
                "source_element_id": "d4-p1-s3"
              },
              {
                "source_element_id": "d4-p1-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Rats with microdialysis probes in prefrontal cortex",
              "observed_outcomes": "Glutamate efflux levels in prefrontal cortex measured by microdialysis with HPLC-fluorescence detection",
              "manipulated_conditions": "Pretreatment with vehicle, clozapine (10 mg/kg), haloperidol (0.1 mg/kg), or M100907 (0.1 mg/kg) followed by PCP (5 mg/kg) administration",
              "control_or_reference_point": "Vehicle pretreatment before PCP administration; baseline glutamate levels collected before drug administration",
              "study_design_or_method_class": "Pharmacological challenge study with microdialysis"
            }
          },
          "created_at": "2025-11-26T12:31:57.370927Z"
        },
        {
          "id": "5489073c-67a6-49fa-b52e-67b7c84b4f45",
          "paper_id": "1eff9f6c-8d38-4ca8-be25-3cd54f4bfc24",
          "job_id": "9c438b46-f6ae-4a08-9454-1591e165b6d0",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Pharmacological intervention study examining the effect of M100907 (5-HT2A antagonist) on PCP-induced dopamine release in cortex and nucleus accumbens, with concurrent behavioral measurements of locomotion and stereotypy",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "d4-p1-s7"
              }
            ],
            "structured_method_description": {
              "study_subject": "Rats with microdialysis probes in prefrontal cortex and nucleus accumbens",
              "observed_outcomes": "Dopamine efflux in cortex and nucleus accumbens measured by microdialysis with HPLC-electrochemical detection; locomotor activity and stereotypy behavior",
              "manipulated_conditions": "Pretreatment with M100907 or vehicle followed by PCP administration",
              "control_or_reference_point": "Vehicle pretreatment before PCP administration; baseline dopamine levels and baseline behavior",
              "study_design_or_method_class": "Pharmacological challenge study with microdialysis and behavioral assessment"
            }
          },
          "created_at": "2025-11-26T12:31:57.370927Z"
        },
        {
          "id": "c6b4ea32-8f11-432c-8dc4-0273eed9690e",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Longitudinal within-subjects design examining the effects of 8 weeks of lithium monotherapy on brain structure (measured via MRI) and peripheral gene expression in bipolar disorder patients, with repeated measurements at baseline, 2 weeks, and 8 weeks, compared against healthy controls assessed at matched timepoints.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s2"
              },
              {
                "source_element_id": "abs-d1-p1-s3"
              },
              {
                "source_element_id": "d2-h1"
              },
              {
                "source_element_id": "d2-p1-s1"
              },
              {
                "source_element_id": "d2-p2-s1"
              },
              {
                "source_element_id": "d2-p2-s2"
              },
              {
                "source_element_id": "d3-h1"
              },
              {
                "source_element_id": "d3-p1-s1"
              },
              {
                "source_element_id": "d3-p1-s2"
              },
              {
                "source_element_id": "d3-p2-s1"
              },
              {
                "source_element_id": "d3-p2-s2"
              },
              {
                "source_element_id": "d3-p2-s3"
              }
            ],
            "structured_method_description": {
              "study_subject": "Bipolar disorder patients aged 18-60 years meeting DSM-IV-TR criteria for current bipolar disorder with (hypo)manic or depressed episode, medication-free for >2 weeks",
              "observed_outcomes": "Brain structural features (gray matter fraction, global cortical thickness, regional cortical thickness, subcortical volumes) measured via MRI; peripheral blood gene expression; clinical symptoms measured by HAMD, YMRS, CGIS, and CGII scales",
              "manipulated_conditions": "8 weeks of lithium monotherapy (300 mg twice daily, titrated to achieve serum levels of 0.5-1.0 mEq/L)",
              "control_or_reference_point": "Baseline measurements before lithium treatment in bipolar patients; untreated healthy controls assessed at matched timepoints (baseline, 2 weeks, 8 weeks)",
              "study_design_or_method_class": "Longitudinal within-subjects intervention study with healthy control comparison"
            }
          },
          "created_at": "2025-11-26T12:25:51.874628Z"
        },
        {
          "id": "12b135c6-42ef-4c3d-853e-8e166dde9037",
          "paper_id": "5f8fef0b-f3bf-4ccc-8ee5-e9d13bc64126",
          "job_id": "ba6f5fe7-4ad2-42a0-91ad-dfc5022451fc",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Integrative analysis correlating concurrent changes in brain structural features and gene expression pathways to identify molecular mechanisms associated with lithium's effects, including mediation analysis to test whether structural changes mediate the relationship between gene expression and clinical symptom improvement.",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s3"
              },
              {
                "source_element_id": "abs-d1-p1-s7"
              },
              {
                "source_element_id": "abs-d1-p1-s9"
              }
            ],
            "structured_method_description": {
              "study_subject": "Relationship between brain structural changes and peripheral gene expression changes in bipolar disorder patients treated with lithium",
              "observed_outcomes": "Correlations between gene pathway expression changes and structural brain changes (9 pathways with FDR < 0.05); mediation effects showing brain structure mediating relationships between gene expression and clinical outcomes",
              "manipulated_conditions": "Linear mixed-effects models applied to identify lithium-associated changes in brain structure and gene expression, followed by correlation of concurrent changes across modalities",
              "control_or_reference_point": "Baseline measurements and statistical correction for multiple testing; FDR-corrected significance thresholds",
              "study_design_or_method_class": "Multi-modal integrative correlation and mediation analysis"
            }
          },
          "created_at": "2025-11-26T12:25:51.874628Z"
        },
        {
          "id": "6b4d147b-9aac-4f44-8f5d-e071ad499529",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "RNA-sequencing study of lithium-treated versus non-treated rats to identify genes regulated by lithium exposure, comparing corpus callosum tissue from 8 lithium-treated rats against 9 control rats",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s5"
              },
              {
                "source_element_id": "abs-d1-p1-s6"
              },
              {
                "source_element_id": "abs-d1-p1-s7"
              }
            ],
            "structured_method_description": {
              "study_subject": "Corpus callosum tissue from rats",
              "observed_outcomes": "Gene expression levels measured via RNA-sequencing",
              "manipulated_conditions": "Lithium treatment exposure",
              "control_or_reference_point": "Non-treated rats (n=9)",
              "study_design_or_method_class": "Between-subjects experimental design with RNA-sequencing"
            }
          },
          "created_at": "2025-11-26T12:29:54.140420Z"
        },
        {
          "id": "8b422ceb-e26f-458e-be8c-2d8e183a3b91",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Expression quantitative trait loci (eQTL) analysis to identify genes with differential expression in bipolar disorder, mapping BD-associated genetic variants from GWAS to gene expression using three different expression databases",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s8"
              },
              {
                "source_element_id": "abs-d1-p1-s9"
              }
            ],
            "structured_method_description": {
              "study_subject": "BD-associated genetic variants from genome-wide association study",
              "observed_outcomes": "Gene expression levels regulated by BD-associated variants",
              "manipulated_conditions": "Genetic variants associated with bipolar disorder",
              "control_or_reference_point": "Baseline gene expression patterns from three gene expression databases",
              "study_design_or_method_class": "eQTL mapping study"
            }
          },
          "created_at": "2025-11-26T12:29:54.140420Z"
        },
        {
          "id": "87bf24e0-ca0f-40b8-a9a7-21db12bbd1e2",
          "paper_id": "9ee34aa7-3003-41e4-a3f7-7cf0e53ed274",
          "job_id": "9efc1ac9-f69c-40c6-aa6e-a6302612845f",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Differential gene expression analysis comparing brain tissue from bipolar disorder patients versus healthy controls to validate candidate genes identified from prior analyses",
            "source_elements": [
              {
                "source_element_id": "abs-d1-p1-s4"
              },
              {
                "source_element_id": "abs-d1-p1-s10"
              },
              {
                "source_element_id": "abs-d1-p1-s11"
              },
              {
                "source_element_id": "abs-d1-p1-s12"
              }
            ],
            "structured_method_description": {
              "study_subject": "Corpus callosum brain tissue from humans (42 BD patients and 42 healthy controls)",
              "observed_outcomes": "Expression levels of candidate genes (particularly RPS23 and GRIN2A)",
              "manipulated_conditions": "Bipolar disorder diagnostic status",
              "control_or_reference_point": "Healthy control subjects (n=42)",
              "study_design_or_method_class": "Case-control differential expression analysis"
            }
          },
          "created_at": "2025-11-26T12:29:54.140420Z"
        },
        {
          "id": "c0385795-90d3-4532-9275-b829e10b36c4",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects design testing the effect of age-related AÎ² accumulation on spatial reference memory in transgenic Tg2576 mice compared to non-transgenic littermates using the Morris water maze",
            "source_elements": [
              {
                "source_element_id": "d2-p1-s1"
              },
              {
                "source_element_id": "d2-p1-s2"
              },
              {
                "source_element_id": "d2-p1-s3"
              },
              {
                "source_element_id": "d2-p1-s4"
              },
              {
                "source_element_id": "d2-p1-s5"
              },
              {
                "source_element_id": "d2-p1-s6"
              },
              {
                "source_element_id": "d2-p1-s7"
              }
            ],
            "structured_method_description": {
              "study_subject": "Tg2576 transgenic mice (expressing human amyloid precursor protein) and non-transgenic littermate controls in B6SJL background strain",
              "observed_outcomes": "Spatial reference memory performance measured by target quadrant occupancy in probe trials and escape latency during hidden platform training in Morris water maze",
              "manipulated_conditions": "Genetic manipulation (Tg2576 transgene-positive versus transgene-negative mice) leading to differential amyloid-Î² protein assembly in the brain",
              "control_or_reference_point": "Transgene-negative littermate mice",
              "study_design_or_method_class": "Between-subjects transgenic animal model with behavioral testing"
            }
          },
          "created_at": "2025-11-26T11:16:18.342620Z"
        },
        {
          "id": "519e1d37-f5eb-422f-a17c-cdc0736d069b",
          "paper_id": "a1ccbd68-78dd-46e0-841b-08427704a08a",
          "job_id": "873643f5-bc1a-4c1c-8e3d-1b5c3310804f",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Within- and between-subjects design testing the causal effect of intracerebroventricular infusion of AÎ²*56 oligomers on spatial learning and memory in adult rats using the Morris water maze",
            "source_elements": [
              {
                "source_element_id": "d2-p2-s1"
              },
              {
                "source_element_id": "d2-p2-s2"
              },
              {
                "source_element_id": "d2-p2-s3"
              },
              {
                "source_element_id": "d2-p2-s4"
              },
              {
                "source_element_id": "d2-p2-s5"
              },
              {
                "source_element_id": "d2-p2-s6"
              },
              {
                "source_element_id": "d2-p2-s7"
              },
              {
                "source_element_id": "d2-p2-s8"
              },
              {
                "source_element_id": "d2-p2-s9"
              },
              {
                "source_element_id": "d2-p2-s10"
              },
              {
                "source_element_id": "d2-p2-s11"
              },
              {
                "source_element_id": "d2-p2-s12"
              },
              {
                "source_element_id": "d2-p2-s13"
              },
              {
                "source_element_id": "d2-p2-s14"
              },
              {
                "source_element_id": "d2-p2-s15"
              },
              {
                "source_element_id": "d2-p2-s16"
              },
              {
                "source_element_id": "d2-p2-s17"
              },
              {
                "source_element_id": "d2-p2-s18"
              },
              {
                "source_element_id": "d2-p2-s19"
              },
              {
                "source_element_id": "d2-p2-s20"
              },
              {
                "source_element_id": "d2-p2-s21"
              },
              {
                "source_element_id": "d2-p2-s22"
              },
              {
                "source_element_id": "d2-p2-s23"
              },
              {
                "source_element_id": "d2-p2-s24"
              },
              {
                "source_element_id": "d2-p2-s25"
              },
              {
                "source_element_id": "d2-p2-s26"
              }
            ],
            "structured_method_description": {
              "study_subject": "Young adult male Long-Evans rats (approximately 4 months of age)",
              "observed_outcomes": "Spatial learning (escape latency during hidden platform training trials) and memory retention (percentage of time spent in annulus 1.5Ã the size of target platform during probe trial; learning index)",
              "manipulated_conditions": "Intracerebroventricular infusion of AÎ²*56 oligomers (0.85 mM, 10 Î¼l) versus vehicle (50 mM ammonium acetate buffer, pH 8.5) administered 2 hours before training and 2 hours before retention probe trial",
              "control_or_reference_point": "Vehicle-infused rats matched for body weight and pre-training learning index; within-subjects baseline established through pre-training and subsequent re-testing without infusions",
              "study_design_or_method_class": "Intracerebroventricular infusion study with behavioral assessment in rodent model"
            }
          },
          "created_at": "2025-11-26T11:16:18.342620Z"
        },
        {
          "id": "a084af9e-8a41-4a18-992f-cb561f86e62c",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological manipulation testing the effects of chronic PKC inhibition (14 days tamoxifen or chelerythrine treatment) on adult hippocampal cell proliferation measured by BrdU labeling in rats",
            "source_elements": [
              {
                "source_element_id": "d6-p1-s6"
              },
              {
                "source_element_id": "d14-p1-s1"
              },
              {
                "source_element_id": "d14-p1-s2"
              },
              {
                "source_element_id": "d14-p1-s3"
              },
              {
                "source_element_id": "d14-p1-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Adult rats with focus on hippocampal dentate gyrus cell proliferation",
              "observed_outcomes": "Number of BrdU-labeled proliferating cells in the granule cell layer and subgranular zone of the dorsal and ventral hippocampus, quantified via light microscopy",
              "manipulated_conditions": "14 daily injections of PKC inhibitors (tamoxifen 10 mg/kg/day i.p. or chelerythrine 0.3 mg/kg/day s.c.) versus vehicle control; BrdU administered on day 13",
              "control_or_reference_point": "Vehicle-treated control rats",
              "study_design_or_method_class": "Between-subjects chronic pharmacological intervention with immunohistochemical cell counting"
            }
          },
          "created_at": "2025-11-26T13:09:47.563854Z"
        },
        {
          "id": "111f61c1-05bf-4803-9454-c031a6d08406",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological manipulation testing the effects of acute PKC inhibition (tamoxifen or chelerythrine) on amphetamine-induced hyperlocomotion in rats",
            "source_elements": [
              {
                "source_element_id": "d6-p1-s1"
              }
            ],
            "structured_method_description": {
              "study_subject": "Adult rats exhibiting amphetamine-induced hyperlocomotion",
              "observed_outcomes": "Locomotor activity levels (hyperlocomotion)",
              "manipulated_conditions": "Acute administration of PKC inhibitors (tamoxifen 80 mg/kg i.p. or chelerythrine 3 mg/kg s.c.) versus vehicle control, given 60 minutes before amphetamine injection",
              "control_or_reference_point": "Vehicle-treated rats receiving amphetamine",
              "study_design_or_method_class": "Between-subjects pharmacological intervention study"
            }
          },
          "created_at": "2025-11-26T13:09:47.563854Z"
        },
        {
          "id": "4741ff9e-5b7a-4dc9-89b6-c98eb62a1d73",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological manipulation testing the effects of acute PKC modulation (inhibitors: tamoxifen or chelerythrine; activator: PMA) on risk-taking behavior measured by open field and elevated plus maze tests in rats",
            "source_elements": [
              {
                "source_element_id": "d6-p1-s2"
              },
              {
                "source_element_id": "d6-p1-s3"
              },
              {
                "source_element_id": "d6-p1-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Adult rats",
              "observed_outcomes": "Risk-taking behavior assessed via open field test and elevated plus maze test",
              "manipulated_conditions": "Acute administration of PKC inhibitors (tamoxifen or chelerythrine given 60 min before test) versus PKC activator (PMA administered i.c.v. 40 min before test or intrahippocampal 10 min before test) versus vehicle control",
              "control_or_reference_point": "Vehicle-treated control rats",
              "study_design_or_method_class": "Between-subjects pharmacological intervention study with behavioral testing"
            }
          },
          "created_at": "2025-11-26T13:09:47.563854Z"
        },
        {
          "id": "9c31dcdc-f814-44b0-aaca-3fe6364aabe5",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological manipulation testing the effects of acute and chronic PKC modulation (inhibitors: tamoxifen or chelerythrine; activator: PMA) on depression-like behavior in the forced swim test in rats",
            "source_elements": [
              {
                "source_element_id": "d6-p1-s5"
              }
            ],
            "structured_method_description": {
              "study_subject": "Adult rats",
              "observed_outcomes": "Depression-like behavior measured by immobility time in forced swim test",
              "manipulated_conditions": "Acute i.c.v. PMA infusion (40 min before test) versus single injection of PKC inhibitors (tamoxifen or chelerythrine, 60 min before test) versus 14 daily injections of PKC inhibitors (last injection 60 min before test) versus vehicle control",
              "control_or_reference_point": "Vehicle-treated control rats",
              "study_design_or_method_class": "Between-subjects pharmacological intervention study with acute and chronic treatment arms"
            }
          },
          "created_at": "2025-11-26T13:09:47.563854Z"
        },
        {
          "id": "3d4db5bc-9305-45d0-b5e1-bc1db954dd2a",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological manipulation testing the effects of acute PKC inhibition (tamoxifen or chelerythrine) on amphetamine-induced hyperlocomotion in rats",
            "source_elements": [
              {
                "source_element_id": "d6-p1-s1"
              }
            ],
            "structured_method_description": {
              "study_subject": "Adult rats exhibiting amphetamine-induced hyperlocomotion",
              "observed_outcomes": "Locomotor activity levels (hyperlocomotion)",
              "manipulated_conditions": "Acute administration of PKC inhibitors (tamoxifen 80 mg/kg i.p. or chelerythrine 3 mg/kg s.c.) versus vehicle control, given 60 minutes before amphetamine injection",
              "control_or_reference_point": "Vehicle-treated rats receiving amphetamine",
              "study_design_or_method_class": "Between-subjects pharmacological intervention study"
            }
          },
          "created_at": "2025-11-26T12:33:07.265424Z"
        },
        {
          "id": "c25ffd4a-2681-4f96-815f-90b4eb142477",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological manipulation testing the effects of acute PKC modulation (inhibitors: tamoxifen or chelerythrine; activator: PMA) on risk-taking behavior measured by open field and elevated plus maze tests in rats",
            "source_elements": [
              {
                "source_element_id": "d6-p1-s2"
              },
              {
                "source_element_id": "d6-p1-s3"
              },
              {
                "source_element_id": "d6-p1-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Adult rats",
              "observed_outcomes": "Risk-taking behavior assessed via open field test and elevated plus maze test",
              "manipulated_conditions": "Acute administration of PKC inhibitors (tamoxifen or chelerythrine given 60 min before test) versus PKC activator (PMA administered i.c.v. 40 min before test or intrahippocampal 10 min before test) versus vehicle control",
              "control_or_reference_point": "Vehicle-treated control rats",
              "study_design_or_method_class": "Between-subjects pharmacological intervention study with behavioral testing"
            }
          },
          "created_at": "2025-11-26T12:33:07.265424Z"
        },
        {
          "id": "753af1d3-0b73-4135-8629-6770fe6877c0",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological manipulation testing the effects of acute and chronic PKC modulation (inhibitors: tamoxifen or chelerythrine; activator: PMA) on depression-like behavior in the forced swim test in rats",
            "source_elements": [
              {
                "source_element_id": "d6-p1-s5"
              }
            ],
            "structured_method_description": {
              "study_subject": "Adult rats",
              "observed_outcomes": "Depression-like behavior measured by immobility time in forced swim test",
              "manipulated_conditions": "Acute i.c.v. PMA infusion (40 min before test) versus single injection of PKC inhibitors (tamoxifen or chelerythrine, 60 min before test) versus 14 daily injections of PKC inhibitors (last injection 60 min before test) versus vehicle control",
              "control_or_reference_point": "Vehicle-treated control rats",
              "study_design_or_method_class": "Between-subjects pharmacological intervention study with acute and chronic treatment arms"
            }
          },
          "created_at": "2025-11-26T12:33:07.265424Z"
        },
        {
          "id": "8b00dc4e-9d97-40d9-b62e-6dd5f0b05c62",
          "paper_id": "cff3064b-6a8c-4e61-ba97-0ee25e061e78",
          "job_id": "e6cf714d-38d7-41e5-a4e1-e3a0bd3aa619",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Between-subjects pharmacological manipulation testing the effects of chronic PKC inhibition (14 days tamoxifen or chelerythrine treatment) on adult hippocampal cell proliferation measured by BrdU labeling in rats",
            "source_elements": [
              {
                "source_element_id": "d6-p1-s6"
              },
              {
                "source_element_id": "d14-p1-s1"
              },
              {
                "source_element_id": "d14-p1-s2"
              },
              {
                "source_element_id": "d14-p1-s3"
              },
              {
                "source_element_id": "d14-p1-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Adult rats with focus on hippocampal dentate gyrus cell proliferation",
              "observed_outcomes": "Number of BrdU-labeled proliferating cells in the granule cell layer and subgranular zone of the dorsal and ventral hippocampus, quantified via light microscopy",
              "manipulated_conditions": "14 daily injections of PKC inhibitors (tamoxifen 10 mg/kg/day i.p. or chelerythrine 0.3 mg/kg/day s.c.) versus vehicle control; BrdU administered on day 13",
              "control_or_reference_point": "Vehicle-treated control rats",
              "study_design_or_method_class": "Between-subjects chronic pharmacological intervention with immunohistochemical cell counting"
            }
          },
          "created_at": "2025-11-26T12:33:07.265424Z"
        },
        {
          "id": "ed8c34be-5a46-4fc3-b315-1563ba31d333",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Placebo-controlled crossover study testing the effect of intravenous ketamine infusion (0.5 mg/kg over 40 min) versus placebo on depressive symptoms in treatment-resistant depression patients",
            "source_elements": [
              {
                "source_element_id": "d3-p1-s1"
              },
              {
                "source_element_id": "d3-p1-s2"
              },
              {
                "source_element_id": "d3-p1-s3"
              }
            ],
            "structured_method_description": {
              "study_subject": "Patients with treatment-resistant unipolar or bipolar depression",
              "observed_outcomes": "Antidepressant response measured at various time points post-infusion (maximal effects at 72 hours)",
              "manipulated_conditions": "Intravenous infusion of sub-anesthetic ketamine (0.5 mg/kg over 40 min) versus placebo",
              "control_or_reference_point": "Placebo infusion",
              "study_design_or_method_class": "Placebo-controlled crossover trial"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "bda6137d-beff-40c7-bbe3-4db4275146b5",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Double-blind, placebo-controlled crossover clinical trial examining the antidepressant response to ketamine infusion in treatment-resistant depressive patients with unipolar and bipolar depression",
            "source_elements": [
              {
                "source_element_id": "d3-p1-s4"
              },
              {
                "source_element_id": "d3-p1-s5"
              }
            ],
            "structured_method_description": {
              "study_subject": "Treatment-resistant depressive (TRD) patients with unipolar and bipolar depression",
              "observed_outcomes": "Antidepressant response rate (71% response) and time course of improvement (significant at 110 min, maximal at 24 h, lasting up to 7 days)",
              "manipulated_conditions": "Ketamine infusion versus placebo",
              "control_or_reference_point": "Placebo infusion",
              "study_design_or_method_class": "Double-blind, placebo-controlled crossover trial"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "c9c40336-98d5-4ed3-812c-88555959ddd7",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Two-site, parallel arm, randomized controlled trial comparing single ketamine infusion to active placebo control (midazolam) in treatment-resistant depression patients",
            "source_elements": [
              {
                "source_element_id": "d3-p2-s2"
              }
            ],
            "structured_method_description": {
              "study_subject": "Treatment-resistant depression patients",
              "observed_outcomes": "Antidepressant response rate at 24 hours post-infusion",
              "manipulated_conditions": "Single infusion of ketamine versus midazolam (anesthetic control)",
              "control_or_reference_point": "Midazolam (active placebo control)",
              "study_design_or_method_class": "Randomized controlled trial with active placebo control"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "40e2d5ed-d745-4428-83f5-d0bcaabbf1df",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Double-blind, placebo-controlled trial testing the sustained antidepressant response to a single intravenous ketamine dose (0.5 mg/kg) over 4 weeks in treatment-resistant depression",
            "source_elements": [
              {
                "source_element_id": "d3-p2-s3"
              },
              {
                "source_element_id": "d3-p2-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Treatment-resistant depression patients",
              "observed_outcomes": "Sustained antidepressant response at 4 weeks post-treatment (27% maintained response)",
              "manipulated_conditions": "Single intravenous ketamine dose (0.5 mg/kg) versus placebo",
              "control_or_reference_point": "Placebo",
              "study_design_or_method_class": "Double-blind, placebo-controlled trial"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "1d989ce1-be8c-43ed-8699-b189ff099160",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Open-label study evaluating rapid antidepressant effects of low-dose intravenous ketamine (0.2 mg/kg) administered via fast infusion (1-2 min) in emergency depressed patients with suicidal ideation",
            "source_elements": [
              {
                "source_element_id": "d3-p2-s5"
              },
              {
                "source_element_id": "d3-p2-s6"
              }
            ],
            "structured_method_description": {
              "study_subject": "Emergency depressed patients with marked suicidal ideation",
              "observed_outcomes": "Reduction in severity of depressive symptoms and suicidal ideation",
              "manipulated_conditions": "Low-dose ketamine (0.2 mg/kg, i.v.) administered via rapid infusion (1-2 min)",
              "control_or_reference_point": "Baseline depressive symptoms before ketamine administration",
              "study_design_or_method_class": "Open-label clinical study"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "0ed59e18-395d-4153-9630-cd4ef25d3a6c",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Open-label study examining safety and efficacy of repeated-dose intravenous ketamine (up to six infusions, 3 times weekly over 12 days) in unmedicated treatment-resistant depression patients, measuring time to relapse among responders",
            "source_elements": [
              {
                "source_element_id": "d3-p3-s2"
              },
              {
                "source_element_id": "d3-p3-s3"
              },
              {
                "source_element_id": "d3-p3-s4"
              },
              {
                "source_element_id": "d3-p3-s5"
              }
            ],
            "structured_method_description": {
              "study_subject": "Unmedicated treatment-resistant depression patients under antidepressant washout",
              "observed_outcomes": "Time to relapse after treatment (median 18 days) and predictive value of early response (4 hr) for sustained response",
              "manipulated_conditions": "Repeated intravenous ketamine infusions (up to 6 times, 3 times weekly over 12 days)",
              "control_or_reference_point": "Baseline pre-treatment state and response to initial ketamine infusion",
              "study_design_or_method_class": "Open-label repeated-dose study"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "9f0de866-4b40-471b-9d85-3625790b7003",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Clinical trial comparing intranasal ketamine (50 mg single dose) to placebo for treatment of depressive symptoms in treatment-resistant depression, measuring improvement at 24 hours",
            "source_elements": [
              {
                "source_element_id": "d3-p4-s2"
              },
              {
                "source_element_id": "d3-p4-s3"
              }
            ],
            "structured_method_description": {
              "study_subject": "Treatment-resistant depression patients",
              "observed_outcomes": "Depressive symptom improvement at 24 hours post-administration",
              "manipulated_conditions": "Intranasal ketamine administration (50 mg single dose) versus placebo",
              "control_or_reference_point": "Placebo",
              "study_design_or_method_class": "Placebo-controlled trial testing alternative administration route"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "e7afdb77-fc67-4b4c-88fc-f7d62e9a5a55",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Clinical trial comparing the antidepressant response and psychotomimetic effects of the NMDA receptor antagonist Lanicemine (AZD6765) versus ketamine in treatment-resistant depression",
            "source_elements": [
              {
                "source_element_id": "d3-p7-s3"
              },
              {
                "source_element_id": "d3-p7-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Treatment-resistant depression patients",
              "observed_outcomes": "Onset and rate of antidepressant action (measured at 80 min post-administration) and psychotomimetic side effects",
              "manipulated_conditions": "Lanicemine (low-affinity NMDA receptor antagonist) versus ketamine",
              "control_or_reference_point": "Ketamine treatment",
              "study_design_or_method_class": "Comparative efficacy trial"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "cdcadac1-1649-4778-ae04-d01c76d4d42e",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Biomarker study examining pretreatment serum serine and vitamin B12 plasma concentrations as predictors of ketamine antidepressant response in treatment-resistant depression patients",
            "source_elements": [
              {
                "source_element_id": "d3-p8-s2"
              },
              {
                "source_element_id": "d3-p8-s3"
              },
              {
                "source_element_id": "d3-p8-s4"
              }
            ],
            "structured_method_description": {
              "study_subject": "Treatment-resistant depression patients receiving ketamine treatment",
              "observed_outcomes": "Association between pretreatment serine/vitamin B12 levels and ketamine response status (responder vs non-responder)",
              "manipulated_conditions": "N/A - observational comparison of biomarkers",
              "control_or_reference_point": "Ketamine non-responder patients",
              "study_design_or_method_class": "Biomarker prediction study"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "3007b5bc-5f5f-4e6e-9bab-fe448a8bc0a7",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Magnetoencephalography study examining neural activity in the anterior cingulate cortex during presentation of affectively-charged stimuli as a predictor of ketamine antidepressant response",
            "source_elements": [
              {
                "source_element_id": "d3-p9-s1"
              }
            ],
            "structured_method_description": {
              "study_subject": "Treatment-resistant depression patients receiving ketamine treatment",
              "observed_outcomes": "Anterior cingulate cortex activity predicting antidepressant response to ketamine",
              "manipulated_conditions": "Presentation of affectively-charged stimuli during magnetoencephalography",
              "control_or_reference_point": "Baseline brain activity before ketamine treatment",
              "study_design_or_method_class": "Neuroimaging biomarker prediction study"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        },
        {
          "id": "f0b211b7-5301-419b-a999-279e74562db2",
          "paper_id": "e96d6a98-f38b-4429-b1ba-4c31de579587",
          "job_id": "e637b426-1b83-47f0-8ee7-f61db8b26d01",
          "type": "method",
          "content": {
            "novel_method": false,
            "method_summary": "Clinical study examining changes in plasma BDNF levels and genetic polymorphisms (Val/Val BDNF allele at rs6265) as biomarkers of ketamine antidepressant response in major depressive disorder patients",
            "source_elements": [
              {
                "source_element_id": "d3-p10-s2"
              },
              {
                "source_element_id": "d3-p10-s4"
              },
              {
                "source_element_id": "d3-p10-s5"
              }
            ],
            "structured_method_description": {
              "study_subject": "Major depressive disorder patients receiving ketamine treatment",
              "observed_outcomes": "Association between Val/Val BDNF genotype, plasma BDNF elevation (at 240 min post-infusion), early slow wave activity, and antidepressant response to ketamine",
              "manipulated_conditions": "N/A - observational comparison of BDNF genotypes and plasma BDNF levels",
              "control_or_reference_point": "Met carriers and ketamine non-responders",
              "study_design_or_method_class": "Genetic and biomarker association study"
            }
          },
          "created_at": "2025-11-26T12:24:03.939161Z"
        }
      ]
    },
    "links": [
      {
        "id": "09c82e3b-a9c6-46ce-bf04-76065597972f",
        "from_id": "7f20b8cb-7031-4eda-94a6-62bf085ad3a4",
        "to_id": "574de708-d2c9-4a84-a3ab-666c829c2ca0",
        "content": {
          "link_type": "premise",
          "reasoning": "The metabolite HNK and AMPA receptor activation (claim 7f20b8cb) are mechanistic premises that lead to the downstream effects of increased synaptogenesis and neurotransmission (claim 574de708). The molecular mechanism is the logical foundation for the cellular/circuit-level effects.",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "15ad08af-2602-4905-b7f7-3a99b8bb0112",
        "from_id": "7f20b8cb-7031-4eda-94a6-62bf085ad3a4",
        "to_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "content": {
          "link_type": "premise",
          "reasoning": "The discovery that ketamine works through AMPA receptors and mTOR signaling rather than NMDA antagonism (claim 7f20b8cb) is the mechanistic foundation that supports the broader claim that ketamine represents a paradigm shift demonstrating non-monoaminergic mechanisms (claim 0ff4b45b).",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "8f61448b-6498-4662-ba25-cb2285f021cb",
        "from_id": "c22169ca-25d4-454c-83d7-dc34195e21f6",
        "to_id": "574de708-d2c9-4a84-a3ab-666c829c2ca0",
        "content": {
          "link_type": "variant",
          "reasoning": "Both claims discuss mechanisms of ketamine's antidepressant effects but focus on different aspects. Claim c22169ca identifies Homer1a as a final common pathway, while claim 574de708 focuses on synaptogenesis and serotonergic transmission. These are complementary rather than contradictory mechanisms.",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "e50ecb04-78ca-4d58-a4f0-421fc1a6353a",
        "from_id": "c22169ca-25d4-454c-83d7-dc34195e21f6",
        "to_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "content": {
          "link_type": "premise",
          "reasoning": "The finding that Homer1a mediates effects of multiple antidepressant treatments including ketamine (claim c22169ca) provides mechanistic evidence supporting the broader paradigm shift claim about rapid-acting antidepressants (claim 0ff4b45b).",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "cde2a019-ea52-4553-bd8f-fcacb70105b7",
        "from_id": "54c4e069-99aa-4b45-9a6b-a1c75b1af627",
        "to_id": "7edf49c1-fbb0-4c33-9108-69565003a47c",
        "content": {
          "link_type": "duplicate",
          "reasoning": "Both claims describe essentially the same finding: that SSRI-conjugated siRNAs targeting serotonergic components delivered intranasally produce rapid antidepressant effects. Claim 7edf49c1 adds context about solving delivery/targeting challenges, but the core finding is identical.",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "e874361d-5159-4896-93ab-f0df1e9a2fc5",
        "from_id": "1a636000-95d9-4c4f-8a2d-e203b07f0ad5",
        "to_id": "574de708-d2c9-4a84-a3ab-666c829c2ca0",
        "content": {
          "link_type": "variant",
          "reasoning": "Both claims involve neuroplasticity mechanisms in depression but focus on different brain regions and processes. Claim 1a636000 discusses BDNF and neurogenesis in dentate gyrus, while claim 574de708 discusses synaptogenesis in prefrontal cortex. Both relate to structural plasticity but in different neural systems.",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "d9498f20-d824-4865-a363-479958368397",
        "from_id": "0ccc686b-5be5-4aa5-9360-6c97d148920d",
        "to_id": "bc544bb8-5c5d-4d1e-9c34-b51e2f339464",
        "content": {
          "link_type": "premise",
          "reasoning": "The inhibition of GSK3 and IMPase (claim bc544bb8) serves as the mechanistic premise that explains the wide range of cellular pathway effects on neuroplasticity and neuroprotection described in claim 0ccc686b. The two key molecular targets underlie the diverse downstream effects.",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "c524084f-a0e0-445d-b99e-70890fccecaa",
        "from_id": "bc544bb8-5c5d-4d1e-9c34-b51e2f339464",
        "to_id": "0ccc686b-5be5-4aa5-9360-6c97d148920d",
        "content": {
          "link_type": "premise",
          "reasoning": "The inhibition of GSK3 and IMPase (claim bc544bb8) serves as the mechanistic foundation for lithium's regulatory effects on diverse cellular pathways (claim 0ccc686b). The two key molecular targets explain the downstream effects on neuroplasticity and neuroprotection.",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "a232cd08-6a35-494b-b375-b2cde5fc0a7e",
        "from_id": "bc544bb8-5c5d-4d1e-9c34-b51e2f339464",
        "to_id": "88027d82-ef95-4b58-ad6b-ef7f74e5cb4d",
        "content": {
          "link_type": "premise",
          "reasoning": "GSK3 and IMPase inhibition (claim bc544bb8) are the upstream molecular mechanisms that lead to the specific autophagy enhancement through IP3 signaling (claim 88027d82). The IP3 pathway effect is a consequence of IMPase inhibition.",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "a390055d-dc8c-431f-a27f-d413575b74fd",
        "from_id": "0ccc686b-5be5-4aa5-9360-6c97d148920d",
        "to_id": "49494958-ed3e-4d55-9ca1-fb94f2be3929",
        "content": {
          "link_type": "premise",
          "reasoning": "Lithium's effects on multiple cellular pathways including autophagy (claim 0ccc686b) provides the mechanistic basis for autophagy being the primary mechanism for neuroprotection (claim 49494958). The broad pathway effects support the specific conclusion about autophagy's primacy.",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "6fb0e59f-cc69-4de8-a8dc-f6a645dc673c",
        "from_id": "88027d82-ef95-4b58-ad6b-ef7f74e5cb4d",
        "to_id": "49494958-ed3e-4d55-9ca1-fb94f2be3929",
        "content": {
          "link_type": "premise",
          "reasoning": "The specific mechanism of autophagy enhancement via IP3 signaling (claim 88027d82) serves as mechanistic evidence supporting the broader claim that autophagy promotion is the primary protective mechanism (claim 49494958).",
          "link_category": "claim_to_claim"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:29:14.191179Z"
      },
      {
        "id": "9521ab09-c175-4851-9590-949514853c29",
        "from_id": "54c4e069-99aa-4b45-9a6b-a1c75b1af627",
        "to_id": "1eb5f478-6876-420b-93f5-adce65ce22eb",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "This observation demonstrates rapid antidepressant response (at 24 hours) with ketamine, providing context for what constitutes 'faster changes' in antidepressant treatment, though it uses a different mechanism (NMDA antagonism) than the serotonergic approach in the claim.",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "f0798fc1-01ec-42dc-977d-435645e63c34",
        "from_id": "54c4e069-99aa-4b45-9a6b-a1c75b1af627",
        "to_id": "65723a06-fece-4379-a2c7-5edf633da02d",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "This observation shows that ketamine produces significant improvement as soon as 110 minutes with maximal effects at 24 hours, establishing a benchmark for rapid antidepressant response timelines that helps contextualize the claim's assertion about 'faster changes' compared to traditional SSRIs.",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "75dae15d-ec00-4bf5-8643-bbf74941c30d",
        "from_id": "54c4e069-99aa-4b45-9a6b-a1c75b1af627",
        "to_id": "0183ba53-8992-44ee-9f54-d1f39f1b2807",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "This observation demonstrates very rapid reduction in depression severity with low-dose ketamine, providing context for what rapid-acting antidepressant effects look like, though using a different therapeutic mechanism than the siRNA-SSRI conjugate approach in the claim.",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "67ef1435-cc2f-4393-bb18-9c620421102c",
        "from_id": "54c4e069-99aa-4b45-9a6b-a1c75b1af627",
        "to_id": "2c0bf822-817f-4a5d-9ad9-250b8667a1ac",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "This observation is particularly relevant as it demonstrates rapid antidepressant effects via intranasal administration (same route as the claim) with significant improvement at 24 hours, providing direct context for the feasibility and timeline of intranasal rapid-acting antidepressant delivery.",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "c0cc2c9a-7a0e-4310-bb8e-0e184b79c892",
        "from_id": "54c4e069-99aa-4b45-9a6b-a1c75b1af627",
        "to_id": "e8b1b074-8ba1-4c5f-852f-57c83cde4aa1",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "This observation shows that antidepressant response can be detected as early as 4 hours post-infusion and is predictive of sustained response, providing context for understanding early timepoints of antidepressant action compared to traditional SSRIs which typically require weeks.",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "6afaae34-384d-476c-8c45-3d9a7747f750",
        "from_id": "54c4e069-99aa-4b45-9a6b-a1c75b1af627",
        "to_id": "1d481df7-7085-4d09-a4b4-d79e70359da6",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "This observation shows that ketamine increases plasma BDNF levels at 240 minutes in responders, providing context for rapid changes in biological antidepressant markers, though BDNF is not the same as the 5-HT1A receptor and SERT markers mentioned in the claim.",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "056dd5f1-47eb-4103-b6a9-56c3726fe0ec",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "1eb5f478-6876-420b-93f5-adce65ce22eb",
        "content": {
          "link_type": "supports",
          "reasoning": "Demonstrates ketamine's rapid-acting antidepressant efficacy at 24 hours, which is much faster than traditional monoamine reuptake blockers that typically take weeks to show effects",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "c27cc57a-946c-447c-a148-64cfd1ecf2c8",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "0dfe42c0-20bd-4f9c-a388-7c46b2c51130",
        "content": {
          "link_type": "supports",
          "reasoning": "Shows sustained antidepressant response from a single ketamine dose, demonstrating clinical efficacy beyond the acute phase and supporting the paradigm shift claim",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "e9f7cb25-097e-40cf-b008-77328b79012f",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "45de8027-3e42-46b0-96bf-c388658ef992",
        "content": {
          "link_type": "supports",
          "reasoning": "Demonstrates robust and persistent antidepressant effects in treatment-resistant patients, with maximal effects at 72 hours, illustrating rapid action and efficacy in difficult-to-treat populations where monoamine reuptake blockers have failed",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "a065f275-9c14-4248-9852-2ba675bd41a1",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "20b4c1bf-1c35-4f6e-80d4-438c9c6591d4",
        "content": {
          "link_type": "supports",
          "reasoning": "71% response rate in treatment-resistant depression demonstrates superior efficacy compared to traditional antidepressants in patients who have not responded to monoamine reuptake blockers",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "fa4d8069-3199-42f0-a52a-1eac225e47bf",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "65723a06-fece-4379-a2c7-5edf633da02d",
        "content": {
          "link_type": "supports",
          "reasoning": "Significant improvement occurring as soon as 110 minutes and lasting up to 7 days demonstrates the rapid-acting nature of ketamine, contrasting sharply with the weeks required for monoamine reuptake blockers",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "62d533bd-d893-43bf-9201-d1f851e0072a",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "0183ba53-8992-44ee-9f54-d1f39f1b2807",
        "content": {
          "link_type": "supports",
          "reasoning": "Very robust reduction in severe depression with suicidal ideation demonstrates ketamine's rapid efficacy in emergency psychiatric situations where traditional monoamine-based antidepressants would be too slow-acting",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "0b56c100-60c2-4346-96a9-0b498e28eed1",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "370de8fa-6468-4286-b7f4-5346d69bf925",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "Provides information about the duration of ketamine's effects (median 18 days to relapse), which contextualizes the clinical utility and limitations of this rapid-acting approach",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "fcc6b9a6-d9bc-4949-8a9e-be296a211e49",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "e8b1b074-8ba1-4c5f-852f-57c83cde4aa1",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "The 4-hour predictive timepoint for sustained response provides context about the rapid onset and predictability of ketamine's effects, which differs fundamentally from monoamine-based antidepressants",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "c8b572ee-5a86-46b6-806c-ee9859374d5f",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "2c0bf822-817f-4a5d-9ad9-250b8667a1ac",
        "content": {
          "link_type": "supports",
          "reasoning": "Demonstrates rapid antidepressant action (24 hours) via intranasal route, supporting the claim about ketamine's rapid-acting properties and showing efficacy through alternative administration routes",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "d03c0345-3089-4a48-8c13-840ee665744c",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "af5fdbe3-d00d-4fb2-b318-550d2aa642d6",
        "content": {
          "link_type": "supports",
          "reasoning": "Lanicemine, another NMDA receptor antagonist, showing comparable rapid onset of action (80 minutes) provides evidence that the non-monoaminergic NMDA antagonist mechanism can produce rapid antidepressant effects, supporting the paradigm shift claim",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "185b000f-ed87-48d8-9bc0-aedfd8b6590d",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "0a79d1dd-2ffe-4b55-b7cb-e5a92dee0de0",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "Finding that psychotomimetic effects are not necessary for antidepressant action provides context about the mechanism of ketamine's effects and implications for developing related drugs with better side effect profiles",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "d63b7453-df47-48bf-9800-1cc4832ad535",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "c03b4a3c-fd6c-453b-b892-de0bc60c4cc5",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "Serine plasma concentrations as a predictor of ketamine response provides context about biological mechanisms underlying ketamine's effects, potentially related to its non-monoaminergic NMDA receptor mechanism",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "ee89b8f5-702e-417c-95ee-8bcf77415e81",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "30a13429-ce9c-412f-bf23-f89c1f6c1e33",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "Vitamin B12 association with ketamine response in bipolar patients provides context about biological factors influencing ketamine's efficacy, potentially related to its NMDA receptor mechanism",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "ab6240ec-a26b-430f-b76f-5bd71af62dec",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "1d481df7-7085-4d09-a4b4-d79e70359da6",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "Rapid increase in BDNF levels (240 minutes post-infusion) provides mechanistic context about how ketamine's non-monoaminergic effects may translate to rapid antidepressant action through neuroplasticity pathways",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "299a59de-4280-4a35-93ac-f9aaf9560e91",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "59806c7f-1e1c-44d6-bd97-70873198be59",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "BDNF genetic polymorphism predicting ketamine response provides context about individual variability in response to this non-monoaminergic mechanism",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      },
      {
        "id": "82058a06-fa76-4664-bee4-45c89d615788",
        "from_id": "0ff4b45b-d46b-405d-8744-56b371122414",
        "to_id": "4bafb619-d557-4778-806e-c63b4e143e7b",
        "content": {
          "link_type": "contextualizes",
          "reasoning": "Simultaneous elevation of BDNF and slow wave activity in responders provides mechanistic context about the neurobiological changes underlying ketamine's rapid antidepressant effects through non-monoaminergic pathways",
          "link_category": "claim_to_observation"
        },
        "job_id": "76286a2d-8d0e-4dc9-9332-9cc938eab34c",
        "created_at": "2025-11-27T16:39:08.176950Z"
      }
    ]
  }
}